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Abstract 
 Angelman Syndrome (AS) is a neurodevelopment disorder for which there is currently no 
cure that is characterized by severe seizures, intellectual disability, absent speech, ataxia, and 
happy affect. Loss of expression from the maternally inherited copy of UBE3A, a gene regulated 
by genomic imprinting, causes AS. Currently there are multiple promising therapeutic 
approaches being explored and developed for AS, some of which involve targeting or 
expression of the human genetic sequence. Subsequently, it is necessary to establish robust 
cellular models for AS that can be used to test these, as well as future, potential AS therapies. 
Toward this aim, here we have used the CRISPR/Cas9 genome editing system to generate 
several isogenic human pluripotent stem cell lines two achieve two primary goals. First, we 
aimed to establish a robust quantitative molecular phenotype for cultured human AS neurons 
using the transcriptome. We identified and validated a list of genes that are consistent 
differentially expressed in AS neurons when compared to isogenic controls that can be assayed 
following drug treatments. Second, we aimed to study the abundance and localization of the 
three human UBE3A protein isoforms. We found that isoform 1 is the predominant protein 
isoform, and that UBE3A, regardless of isoform, appears to localize mostly to the cytoplasm, 
with low levels of expression in the nucleus and other organelles. The work in this thesis 
demonstrates that differentially expressed genes can be used as a phenotype for AS neurons to 
measure the effects of potential therapies, and provides important and previously unknown 
information as to the abundance and localization of the human UBE3A protein isoforms in 
human neurons. 
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Chapter 1 
Angelman Syndrome, a genomic imprinting disorder of chromosome 15q11-q13.1  
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General introduction 
 The human chromosomal locus 15q11-q13.1 is subject to genomic imprinting1 – the 
epigenetic phenomenon that produces a differential expression of a gene or genes in a parent 
of origin-specific manner. Unlike most genes which are expressed from both copies of a given 
chromosome, imprinted genes are expressed from only one copy of a chromosome – either the 
one inherited from the mother (the maternal allele) or the one inherited from the father (the 
paternal allele). In addition to imprinting, chromosome 15q11-q13.1 is also subject to 
chromosomal rearrangements (deletions or duplications) during meiosis due to the presence of 
regions of repetitive sequence (low-copy repeats) that are referred to as breakpoints.2 During 
meiosis, these breakpoints can misalign and result in non-allelic homologous recombination, 
producing the subsequent deletions or duplications. Due to this combination of imprinted genes 
and susceptibility to deletions/duplications, three distinct disorders can arise from mutations in 
this region, depending on the nature of the mutation and which copy of the chromosome is 
affected.3 Deletions of the paternal chromosome produce Prader-Willi Syndrome (PWS), 
deletions of the maternal chromosome produce Angelman Syndrome (AS), and duplications of 
the maternal chromosome cause 15q11-q13 Duplication Syndrome (Dup15q). Each of these 
disorders occurs at a frequency of about 1 in 15,000 live births.4  
 
Genomic imprinting at chromosome 15q11-q13.1 
Genomic Imprinting 
While most genes in the mammalian genome are expressed biallelically, a small 
proportion of genes are subject to genomic imprinting. These genes carry epigenetic marks that 
are indicative of the chromosome’s parent of origin (maternal or paternal), which results in the 
silencing of one copy of the gene. Most imprinted genes are found in clusters, and the imprinting 
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of each cluster is typically controlled by an imprinting control region (ICR). Imprinting occurs due 
to differential methylation at these ICRs, with the silenced allele being methylated and the active 
allele being unmethylated.5,6 Methylation of the ICR occurs in the germline: during embryonic 
development, primordial germ cells migrate to the genital ridge, where they undergo global 
demethylation, causing the previous pattern of imprints from both parents to be erased. In 
oocytes, methylation of ICRs occurs after birth, while in male germ cells, methylation is mostly 
complete by birth. The majority of methylated ICRs are on the maternal allele.5  
In addition to methylation at ICRs, imprinting of genes also can involve non-coding RNAs 
(such as UBE3A-ATS, KCNQ1OT1),7 histone modifications (such as H3K4 methylation in male 
germ cells), and transcription.6 While the exact evolutionary purpose of genomic imprinting is 
not known, it is known that imprinting in mammals is associated with evolution of the placenta. 
One theory is that imprinting could have evolved as a way to regulate the dosage of certain 
genes. Imprinted genes seem to be involved in important processes such as prenatal growth, 
placental growth, lineage development, normal brain function, and postnatal energy 
homeostasis. Mouse embryos in which both sets of chromosomes are inherited from one parent 
display gross developmental abnormalities.5,8  
15q11-q13.1 
 The 15q11-q13.1 region is approximately 6 Mb in length, consisting of both imprinted 
and biallelically-expressed genes (Figure 1). The region contains 3 areas of low-copy repeats, 
known as breakpoints, that result in an increased likelihood for deletions and duplications to 
occur curing meiosis (Figure 1, jagged lines). The genes located between breakpoints 1 and 2 
(BP1 and BP2) are biallelically expressed (TUBGCP5, CYFIP1, NIPA2, NIPA1), while the region 
between BP2 and BP3 contains both imprinted (see below) and biallelically expressed genes 
(GABRB3, GABRA5, GABRG3, OCA2, HERC2, GOLGA8).  
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Imprinted Genes of 15q11-q13.1 
 The region of 15q11-q13 that is subject to genomic imprinting is approximately 2 Mb in 
length and contains both paternally-expressed and maternally-expressed genes.3 Approximately 
15 genes or transcripts are expressed exclusively from the paternal allele. MKRN3, MAGEL2, 
NDN, and C15ORF2 are protein-coding genes. SNURF-SNRPN is a bicistronic transcript that 
encodes two proteins (SNURF and SNRPN) but also serves as host transcript for SNORD107, 
SNORD64, SNORD108, SNORD109A, SNORD116, SNORD115, SNORD109B, and the 
UBE3A-ATS transcripts.9 This transcript spans approximately 600 kb of genomic DNA and 
undergoes alternative splicing. Additionally, the noncoding transcript IPW and two long 
noncoding RNAs (lncRNAs), PWRN1 and PWNR2, are expressed from the paternal allele.10 
The SNORDs belong to a family of noncoding RNAs known as small nucleolar RNAs 
(snoRNAs, Figure 1, vertical black lines). In total, there are 72 snoRNAs produced from 
15q11-q13, all of which are processed from introns of the SNURF-SNRPN transcript.10 IPW, 
SNORD115, SNORD 109B, and UBE3A-ATS are expressed/produced specifically in neurons 
for reasons that are not fully understood. Imprinting of the paternally inherited genes is due to 
CpG methylation at SNRPN, NDN, and MKRN3 on the maternal allele (Figure 1, black 
circles). While the silencing of genes on the maternal allele occurs in all cell types, there is 
neuron-specific imprinting of the UBE3A gene. In non-neuronal cells, UBE3A is expressed 
biallelically. Due to the neuron-specific production of the UBE3A-ATS transcript from the 
paternal allele (Figure 1, dotted line), however, the paternal copy of UBE3A is silenced in 
neurons.11 The exact mechanism by which the UBE3A-ATS transcript silences the paternal 
copy of UBE3A is not known. 
Bipartite imprinting center (AS-IC, PWS-IC) 
 Imprinting of the 15q11-q13 region is controlled by a bipartite imprinting center (IC), 
consisting of the Angelman Syndrome IC (AS-IC; Figure 1, red shaded area) and the Prader-
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Willi Syndrome IC (PWS-IC; Figure 1, blue shaded area). These regions were initially 
identified as the shortest regions of overlap in patients with AS and PWS, respectively, with 
imprinting defect mutations.12 The PWS-IC is approximately 4.3 kb in size and is comprised of 
the major promoter and exon 1 of the SNURF-SNRPN gene. Imprinting (silencing) of genes on 
the maternal allele requires the PWS-IC, as does maintenance of the imprint post-
zygotically.13,14 Additionally, the PWS-IC acts as the canonical promoter for SNRPN and the 
imprinted genes distal to it. The AS-IC is 35 kb upstream of the PWS-IC and is only 880 bp in 
length. While the exact mechanism is not clear, it is known that the AS-IC acts as a repressor of 
the PWS-IC so that the PWS-IC can be methylated on the maternal allele. Interestingly, while 
the AS-IC is required in gametes for the proper establishment of the imprints, it is not required 
later on in development.15 Studies in mouse have confirmed that both the AS-IC and PWS-IC 
together are necessary for imprinting to occur,14,15 and aberrant imprinting at these imprinting 
centers on either the maternal or paternal allele are sufficient to cause Angelman Syndrome or 
Prader-Willi Syndrome respectively.12,16  
 
Disorders Arising from Mutations in 15q11-q13.1 
 The presence of low-copy repeats at certain parts of the chromosome make this region 
susceptible to deletions or duplications due to non-allelic homologous recombination during 
meiosis. Due to the imprinted expression of genes in this region, the phenotypes produced by 
the mutations are dependent upon which copy of the chromosome is affected. 
Prader-Willi Syndrome 
 Loss of expression of the genes from the paternal copy of 15q11-q13 result in Prader-
Willi Syndrome (PWS). Most (~70%) of PWS cases are caused by large deletions of the 
paternal 15q11-q13 region, with another 25% and 5% of cases being caused by maternal 
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uniparental disomy and imprinting defects of the paternal allele, respectively. PWS patients first 
present with hypotonia and failure to thrive in infancy, which manifests as decreased movement, 
lethargy, poor suck, and poor appetite. During childhood, patients develop increased appetite 
which progresses to hyperphagia, which in turn leads to morbid obesity. Additionally, patients 
present with short stature, small hands and feet, hypogonadism, motor and language delay, 
mild to moderate cognitive impairment, characteristic facial features, and behavioral phenotypes 
(temper tantrums, stubbornness, manipulative behavior, and obsessive-compulsive 
characteristics).17 No single gene has been identified whose loss can account for the phenotype 
seen in PWS patients. By studying deletions of various sizes found in both typical- and atypical-
deletion PWS patients, the smallest region identified that, when lost on the paternal allele, 
causes PWS has been narrowed down to approximately 91 kb of DNA that encompasses the 
SNORD116 cluster and the IPW non-coding RNA.18,19 How loss of these RNAs results in the 
PWS phenotype is not understood.  
Angelman Syndrome 
 Loss of the maternal copy of 15q11-q13 results in a clinically distinct syndrome known 
as Angelman Syndrome (AS). AS is characterized by severe seizures, ataxia, motor delay, 
severe intellectual disability, absent speech, and happy demeanor. Patients also commonly 
present with microcephaly, sleep disorder, and hyperactivity. Patients typically begin presenting 
with some AS symptoms as early as 6 to 12 months of age, however the final diagnosis of AS 
typically doesn’t occur until several years after the initial onset of symptoms. Infants with AS 
may have difficulty feeding, gastroesophageal reflux, and hypotonia. Other early (before 1 year 
of age) signs can include happy affect, microcephaly, strabismus, and tremulous movements. 
Seizures and specific changes in EEG tend to present by three years of age. Walking in AS 
patients typically does not occur until between 2 and 6 years of age, although 10% of AS 
patients are unable to walk.20 AS is caused by loss of UBE3A from the maternal copy of the 
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chromosome.21 Most AS cases (~75%) are caused by deletions encompassing 15q11-q13 on 
the maternal allele (Figure 2A).  Mutations in the maternal copy of UBE3A account for another 
10-15% of cases (Figure 2B), with paternal uniparental disomy (Figure 2C) or imprinting 
defects (Figure 2D) of the maternal allele accounting for the remaining cases.22 
15q Duplication Syndrome 
 Duplications of the maternal 15q11-q13 region result in 15q Duplication Syndrome 
(Dup15q). Most (80%) Dup15q patients have a supernumerary isodicentric copy of chromosome 
15, which typically contains two copies of the maternal 15q11-q13 region and two centromeres. 
As of result, these individuals have a tetrasomy of the 15q11-q13 region. The remaining Dup15q 
patients (20%) have an interstitial 15q11-q13 duplication, resulting in two copies of the region in 
tandem on their maternal copy of chromosome 15. Dup15q is characterized by hypotonia, motor 
delay, intellectual disability, epilepsy, and autism spectrum disorder. Indeed, maternal 15q11-13 
duplication is the most common copy number variant associated with autism, accounting for 1-
3% of all cases.23 Like PWS, there is no one gene that accounts for the Dup15q phenotype. 
Because duplications of the paternal allele less severe phenotype that is not fully penetrant, it is 
assumed that UBE3A plays a major role Dup15q. However, duplications of maternal UBE3A 
alone are not sufficient to recapitulate Dup15q,24 so it is likely that other genes within the 
duplication also contribute to the phenotype of these patients.  
 
UBE3A 
UBE3A protein function 
 AS is caused by loss of the maternal copy of 15q11-q13, which results in a loss of 
expression or function of maternal UBE3A. This is due to the fact that the paternal copy of 
UBE3A is imprinted in neurons, therefore AS-causing mutations affect the only functional copy 
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of UBE3A in these cells. The protein encoded by the UBE3A gene, also known as E6-
associated protein (E6-AP), is an E3 ubiquitin ligase.25 Its function is to assemble polyubiquitin 
chains on target proteins so that they can be degraded by the 26S proteasome. UBE3A is the 
founding member of the HECT (Homologous to E6-AP C Terminus) family of E3 ligases, whose 
ubiquitin ligase activity is conferred by a HECT domain.26 Since there are AS patients with 
mutations in the region of UBE3A that encodes the HECT domain, resulting in truncated or 
ligase dead versions of the protein,27,28 it is hypothesized that loss of UBE3A’s E3 ligase activity 
causes AS.  
 Because of its role in AS and in certain cancers, there has been an enormous effort to 
identify robust UBE3A target proteins. Currently, only a handful of these targets are considered 
to be true and reliable substrates.29–33 Unfortunately, the majority of these substrates are not 
necessarily relevant to AS or have not been demonstrated to be substrates in neurons. Many 
other proteins have also been identified as putative UBE3A substrates, however many putative 
substrates have not been validated as actual ubiquitin ligase targets.34–36 In addition, a 
substantial portion of putative UBE3A substrates were identified in the context of various 
cancers.37–39 For these reasons, it is currently unknown how loss of UBE3A in neurons 
specifically causes AS. In addition to its role as an E3 ubiquitin ligase, UBE3A has also been 
identified as transcriptional coactivator.40 However, like the studies identifying its putative 
substrates, this role for UBE3A has yet to be demonstrated in neurons.  
Furthermore, it has been demonstrated that UBE3A can be modulated by other proteins 
in certain contexts. For example, during human papilloma virus (HPV) infection, the HPV 
oncoprotein E6 acts as an allosteric activator of UBE3A, allowing it to target p53 for 
proteasomal degradation, which can lead to cervical cancer.25,41 In the absence of E6, UBE3A 
normally does not ubiquitinate p53. Another example of a UBE3A modulator is another E3 
ligase, HERC2, the gene for which is also located on chromosome 15q11-q13. HERC2 was 
shown to activate the E3 ligase activity of UBE3A in vitro and the two proteins were shown to 
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form a high molecular weight complex independent of the 26S proteasome.35,42 Finally, in the 
process of trying to identify putative substrates, it has also been demonstrated that UBE3A is 
capable of interacting with other proteins without modulating their protein levels.43–45 
Three protein isoforms of UBE3A 
 The human UBE3A gene produces multiple mRNAs that encode for three distinct protein 
isoforms.46,47 All three human isoforms are full length versions of the UBE3A protein and 
presumably have E3 ligase function. Each protein isoform is translated from its own unique 
translational start site, however RNAs for isoforms 2 and 3 contain the translational start site for 
isoform 1.48 Indeed, isoform 1 can be considered the “default” version of the UBE3A protein, 
with isoforms 2 and 3 having an additional 20 and 23 amino acids at their N-termini, 
respectively. The function of these additional amino acids is currently unknown. Additionally, it is 
not known whether the three isoforms share common substrates, localization, or if their 
abundance differs. While the three human isoforms were initially discovered more than 20 years 
ago, few studies have been conducted that explores their roles, abundance, or localization. One 
study of the three mouse protein isoforms demonstrated that dendritic outgrowth phenotypes in 
UBE3A-null cultured neurons could be rescued upon overexpression of mouse isoform 2, but 
not mouse isoforms 1 or 3.49 This study also showed that the mouse isoforms tended to localize 
differently within the cell, with mouse isoform 3 localizing predominantly to the nucleus and 
isoforms 1 and 2 localizing to the cytoplasm in the soma and neuronal processes. The human 
and mouse protein isoforms, however, are not perfectly conserved. Mouse isoform 1 is a 
truncated version of the protein, lacking a HECT domain and therefore lacking E3 ligase activity. 
This isoform was shown to be related to miR-134 in mouse hippocampal neurons.50 Additionally, 
human isoform 2 does not have a mouse equivalent.48 Because of this, it is necessary to study 
the human isoforms of UBE3A to determine whether all three isoforms have a role not only in 
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normal biological function, but also in the various conditions where UBE3A is known to play a 
role (AS, Dup15q, HPV infection). 
The prospect of molecular therapies for Angelman Syndrome 
Symptom-based approaches to AS therapy 
 Currently AS is treated using a symptom management-based approach. The success of 
managing AS symptoms varies from patient to patient, and some symptoms (intellectual 
disability, absent speech) are currently not improved by available treatments.20,51,52 Currently, 
anti-epileptic drugs (AEDs) are prescribed to control seizures, however no one drug is the gold 
standard for seizure treatment in AS. Additionally, it is common for seizure breakthrough to 
occur when patients are treated with a single medication, and some patients’ seizures cannot be 
controlled. Behavior modification therapy can be useful for certain behaviors in AS that are 
considered to be socially disruptive or injurious, while other behaviors, such as hypermotoric 
behavior, tend not to improve with behavioral therapy. Other interventions shown to be 
beneficial in some AS patients include physical therapy, occupational therapy, speech therapy 
and orthopedic braces or surgery. Melatonin has been shown to improve sleep disturbances in 
some AS patients.20 
 At present, there have been only a few studies to examine whether specific drugs could 
improve any AS symptoms. A small study showed reduced seizures in four AS patients who 
were administered the corticosteroid prednisolone.53 Another study of 23 AS patients showed 
improvements in seizures when patients were put on a low glycemic index diet, either alone or 
in conjunction with an AED.54 An open label pilot clinical trial examining the effects of 
minocycline, a tetracycine antibiotic, on AS patients showed improvements on some 
subdomains of the outcome measures, such as communication (Bayley Scales of Infant and 
Toddler Development 3rd Edition), fine motor ability (BSID-III), and auditory comprehension 
(Preschool Language Scale 5th Edition).55 A recent double-blind randomized placebo-controlled 
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study examined whether levodopa (L-dopa) administration lead to improvements patients, 
based on the findings that L-dopa reduced the excessive phosphorylation of CAMKII (Thr286 
and Thr305/306) seen in AS mice. While well tolerated, L-dopa did not produce significant 
improvements in any of the measured outcomes.56 Even more recently, it was announced by 
Ovid Therapeutics that gaboxadol, a delta-selective GABAA receptor agonist, produced 
significant improvements in AS patients in the clinical global impressions of improvement (CGI-I) 
scale when compared to placebo.57  
 
Timing of UBE3A reinstatement in AS mice 
 A major consideration in the development of treatments for neurodevelopmental 
disorders is the earliest age at which patients can be treated, and whether intervention at that 
age, or later ages, will improve the quality of life for these patients. Angelman Syndrome is 
typically diagnosed during early childhood unless prior concerns resulted in prenatal or newborn 
genetic testing. There are two promising gene therapy approaches currently being explored for 
AS: unsilencing of the paternal copy of UBE3A or replacing UBE3A protein by delivery via 
adeno-associated virus (AAV)-based vectors. Both of these approaches rely on the assumption 
that restoring normal UBE3A levels in the brains of AS patients at a later developmental stage 
will be sufficient to overcome months or years of brain development in the absence of UBE3A. 
Recent studies in AS mice have indicated that there is indeed a critical period for UBE3A 
reinstatement to be effective at restoring disease-relevant phenotypes. Restoring UBE3A levels 
in AS mice embryonically rescued all phenotypes assayed (rotarod, marble burying, open field, 
nest building, forced swim, and seizure susceptibility), while partial restoration (30-50%) at P1-
P5 rescued only rotarod and open field phenotypes. Interestingly, only rotarod phenotypes could 
be rescued by restoring UBE3A at juvenile (3 weeks) or adolescent (6 weeks) ages, while adult 
reinstatement (14 weeks) of UEB3A did not rescue any behavioral phenotypes.58 Furthermore, 
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UBE3A reinstatement is capable of rescuing cellular phenotypes even at ages when there is no 
behavioral rescue: adult reinstatement of UBE3A was able to rescue deficits in long-term 
potentiation in the hippocampus58 and synaptic transmission deficits in the medial prefrontal 
cortex.59 
Treating AS by reactivation of the silent paternal UBE3A allele 
 The existence of a silenced but otherwise normal copy of the UBE3A gene on the 
paternal copy of chromosome 15 is one of the most promising therapeutic targets for AS. As 
stated above, the paternal copy of UBE3A is silenced in neurons due to the production of the 
UBE3A-ATS transcript. Gene therapies targeting this antisense transcript could therefore allow 
the paternal copy of UBE3A to be reactivated, and, if done early enough, could produce 
phenotypic improvement in AS patients. Evidence supporting this idea came from an AS mouse 
with a SV40 polyA and neomycin cassette inserted between SNORD115 and UBE3A, which 
was designed to prevent the UBE3A-ATS from overlapping the UBE3A gene. This approach, 
when used in both wildtype and AS mice, was able to upregulate UBE3A expression from the 
paternal allele. It also improved marble burying phenotypes, wire hanging test performance, 
dowel test performance, contextual fear conditioning, and long-term potentiation.60  
 One early attempt to achieve paternal UBE3A unsilencing in AS patients was by 
administering “promethylation supplements”, which would theoretically increase global DNA 
methylation.61,62 It was hoped that this global methylation would include methylation of the PWS-
IC on the paternal allele, which would silence SNURF/SNRPN and therefore prevent production 
of the UBE3A-ATS. Two studies examined the effects of these supplements on AS patients. 
The first was a double-blind placebo-controlled study of the effects of betaine and folic acid.63 
This study did not demonstrate any effects of the treatment on levels of global methylation (as 
measured by levels of methionine and homocysteine) or on developmental outcome measures. 
A second study, a one-year open label study, examined the combination of L-5-
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methyltetrahydrofolate, vitamin B12, betaine, and creatine. As with the first study, there were no 
changes in global DNA methylation or on behavioral outcome measures.64  
 More recent and promising approaches have focused on targeting the already existing 
lncRNA instead of preventing its production. A high-content small molecule screen found that 
topoisomerase type I (TOP1) and type II (TOP2) inhibitors could unsilence the paternal copy of 
UBE3A in cultured mouse neurons. One such TOP1 inhibitor, topotecan, was the most potent 
compound and already an FDA-approved drug for cancer. It was demonstrated that topotecan 
unsilenced paternal UBE3A by causing a downregulation of the UBE3A-ATS, both in vitro and in 
vivo.65 It was also shown that the formation of TOP1 cleavage complexes upon topotecan 
treatment are required to unsilenced paternal UBE3A.66 Further studies determined that 
topotecan decreases the expression of long genes in both mouse and human neurons, 
including almost all genes greater than 200 kb in length, and that many of these long genes are 
autism candidate genes and/or genes that encode synaptic proteins, including NRXN1, NLGN1, 
CNTNAP2, and GABRB3.67 Subsequently, it was shown that topotecan treatment suppresses 
spontaneous network activity and inhibitory neurotransmission, while also reducing excitatory 
neurotransmission.68 Due to a limited bioavailability in the CNS and reports of toxicity, 
alternative TOP1 inhibitors, specifically those derived from indenoisoquinoline, have since been 
investigated. All thirteen of the indenoisoquinoline-derived TOP1 inhibitors tested were able to 
unsilenced the paternal copy of UBE3A in cultured mouse neurons.69 Two of these compounds, 
indotecan and indimitecan are currently in clinical trials for individuals with solid tumors and 
lymphoma.  
 A second approach used to target the UBE3A-ATS transcript was to design antisense 
oligonucleotides (ASOs) specific to the UBE3A-ATS. ASOs are short segments of chemically-
modified oligonucleotides that are designed to be complementary to a transcript of interest. The 
effect of the ASO on the target transcript varies depending on the design of the oligo. ASOs with 
a “gapmer” design (a short segment of unmodified nucleotides flanked by nucleotides with a 
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modified sugar ring) work by inducing RNase H-mediated degradation of their target upon 
binding. This approach was taken to target the UBE3A-ATS in vitro and in vivo.70 In vivo 
administration of the ASOs via intracerebroventricular (i.c.v.) injection produced long-term 
unsilencing (16 weeks) of the paternal allele following a single injection. Additionally, adult mice 
treated with ASO showed improvements in contextual freezing and obesity phenotypes seen in 
AS mice.70  
Expression of exogenous UBE3A using adeno-associated virus-based approaches 
Another therapeutic approach being pursued is to replace UBE3A in AS patients by 
introducing a normal copy UBE3A via an adeno-associated virus (AAV)-based vector. This 
approach was demonstrated to be beneficial in a mouse model of AS using a recombinant 
AAV.71 AS mice receiving the UBE3A-AAV expressed normal levels of UBE3A protein, showed 
a recovery in early phase LTP and post-tetanic potentiation, and showed improvements in both 
contextual fear conditioning and the Morris water maze. Currently, an AAV-based approach for 
UBE3A replacement is in the preclinical stages of development.72 
 
 
 The work outlined in this thesis details the generation and use of isogenic human 
pluripotent stem cell models to study Angelman Syndrome and UBE3A. Generation of these cell 
lines is outlined in Chapter 2. These stem cell lines were then used to establish a robust 
quantitative molecular phenotype for AS (Chapter 3) or to study the three human UBE3A 
protein isoforms (Chapter 4). Knowledge gained from the use of these stem cell models will 
contribute information that is necessary for the development and testing of safe and effective AS 
therapies in cultured human neurons. 
  
15 
 
 
 
 
Figure 1. Map of chromosome 15q11-q13.1 between BP1 and BP3 
Paternally-expressed genes are shown in blue. Maternally expressed genes are shown in red. 
Biallelically expressed genes are shown in light grey. Silenced genes are shown in dark gray. 
Circles indicate differentially methylated regions. Open circles are unmethylated, closed circles 
are methylated. ATP10 is shown as striped because its imprinting status varies between 
individuals. Arrows indicate the direction of transcription. Jagged lines indicate the breakpoints 
caused by low-copy repeats. The dashed/dotted line indicates the long non-coding transcript 
produced by SNURF/SNRPN that serves as the host transcript for the UBE3A-ATS as well as 
the snoRNAs. (Figure based on Chamberlain & Lalande, 2010)3 
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Figure 2. Genetic causes of Angelman Syndrome 
A Deletion of maternal 15q11-q13.1 between BP 1 and BP 3 
B Mutation in maternal UBE3A 
C Paternal uniparental disomy (UPD) 
D Imprinting defect of maternal allele 
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Chapter 2 
Generation of isogenic human pluripotent stem cell lines using CRISPR/Cas9 
 
Some data presented in this chapter was published in the following paper: 
Title: Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem 
cells 
Authors: James J. Fink1, Tiwanna M. Robinson1, Noelle D. Germain2, Carissa L. Sirois2, Kaitlyn 
A. Bolduc2, Amanda J. Ward3, Frank Rigo3, Stormy J. Chamberlain3, & Eric S. Levine1 
1 Department of Neuroscience, University of Connecticut School of Medicine, 263 Farmington 
Avenue, Farmington, Connecticut 06030, USA.  
 
2 Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, 
263 Farmington Avenue, Farmington, Connecticut 06030, USA.  
 
3 Ionis Pharmaceuticals, Carlsbad, California 92010, USA. 
 
My contribution: generation & characterization of UBE3A KO line 
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Background & Rationale 
 Each person’s genome contains its own unique combination of copy number variants 
(CNVs) and single nucleotide variants (SNVs), which can affect overall mRNA expression levels 
and mRNA splicing.73,74 This, coupled with epigenetic factors that can also influence gene 
expression, results in large-scale differences in gene expression between unrelated individuals. 
These gene expression changes can introduce significant variation when trying to establish 
robust cellular models and phenotypes in an in vitro system. Isogenic cell lines remove this 
complication and can also eliminate the need to use a large number of samples, as is typically 
the case when comparing cells from unrelated individuals. The recent adaptation of the bacterial 
adaptive immune system CRISPR-Cas9 for use as an RNA-guided genome editing tool has 
greatly improved the ease with which we can edit the genome in vitro, therefore allowing us to 
more easily generate isogenic cell lines. Importantly, we can edit induced pluripotent or human 
embryonic stem cells using CRISPR technology, allowing us to make precise changes to the 
genome in human cells, which can then be differentiated into disease-relevant cell types. 
 Angelman Syndrome (AS) is caused by the loss of expression of the UBE3A gene on 
the maternal copy of chromosome 15q11-q13.21 Currently there is no treatment or cure for AS, 
however multiple lines of evidence suggest that AS is an ideal candidate for gene therapy-
based approaches. First, studies in mouse have indicated that restoration of UBE3A protein 
levels postnatally can have a phenotypic benefit, depending on the timing of the intervention.58,70 
AS mice in which Ube3a expression has been rescued at a juvenile age recover motor function 
deficits seen during the rotarod task, show some improvement in the forced swim and marble 
burying tasks, and have rescued long-term potentiation (LTP), while mice with adolescent or 
adult Ube3a restoration show less phenotypic improvement. This indicates that therapeutic 
intervention in humans, which in most cases wouldn’t occur until early childhood, may still have 
some therapeutic benefit. Second, the existence of a perfectly good copy of the UBE3A gene on 
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the silenced paternal allele is a promising therapeutic avenue to explore. Indeed, it has been 
shown in mice and in human stem cell derived neurons that preventing the UBE3A-ATS 
transcript from silencing UBE3A, either by degrading it or by preventing its production, results in 
reactivation of the silent paternal copy of UBE3A.60,65,67 Furthermore, it has been shown that 
antisense oligonucleotides specific to the Ube3a-ats in mouse can restore paternal Ube3a in 
vivo and restore some phenotypes in AS mice treated at 2 to 4 months of age.70 
 While the work done in mice has been promising, further advances in developing cures 
or treatments for AS will require the use of human cells or, at the very least, knowledge of the 
human genetic and protein sequences for UBE3A and UBE3A-ATS in order to develop 
therapies that are effective in human patients. Therapeutic approaches that involve targeting the 
UBE3A-ATS transcript need to be tested in human cells, or humanized rodent models, as the 
human transcript is not identical to the mouse transcript.47,75 Vector-based gene therapy 
approaches72 that involve delivery of a UBE3A transgene(s) will require use of the human cDNA 
sequence and also require knowledge of the human UBE3A protein isoforms to know which 
versions of the protein will need to be replaced in patients. Finally, it will also be important to 
test the toxicity of any and all potential AS therapies in human neurons. 
 This chapter outlines the use of the CRISPR/Cas9 genome editing system to edit the 
UBE3A gene in induced pluripotent stem cell (iPSC) and human embryonic stem cell (hESC) 
lines. Some of these cell lines have been used to establish (Chapter 3) or confirm76 robust 
cellular phenotypes for AS stem cell-derived neurons, allowing us to examine these phenotypes 
in cells that are genetically identical aside from their respective UBE3A mutations and be 
confident that these phenotypes are not an artifact of person-to-person variability. Other lines 
generated here have been used to study the abundance and localization of the UBE3A protein 
isoforms (Chapter 4). For this project it was important to make isogenic stem cell lines for two 
reasons. First, we are only aware of AS patients with mutations affecting one of the three 
isoforms (isoform 177), which prevents us from being able to generate iPSCs with mutations 
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affecting the other isoforms simply by reprogramming AS patient fibroblasts. Second, since the 
goal was to examine total UBE3A protein levels upon loss of individual isoforms, any subtle 
changes in protein abundance or localization could be lost by comparing non-isogenic cell lines.  
The knowledge gained by studying these isogenic stem cells and neurons will be useful for the 
development of potential AS therapies: the phenotypes that have been established in isogenic 
AS cells can be assayed following drug treatments, while knowledge of the abundance of each 
isoform can be used to inform UBE3A replacement therapies. 
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Materials and Methods 
iPSC/hESC culture 
Genome editing was performed in AS Pt Mut iPSCs, MCH2-10 iPSCs, and H9 (WA09) 
hESCs. AS Pt Mut iPSCs were derived by reprogramming fibroblasts from a male AS patient 
with a point mutation (T→C) in the UBE3A gene, which results in an amino acid change 
(F583S). This mutation was inherited by both the proband and his brother (also diagnosed with 
AS) from their mother, who in turn had inherited it from her father. MCH2-10 iPSCs were 
derived from a neurotypical female and have been previously described.78,79 All stem cells were 
cultured and maintained as previously described.78,79 Briefly, stem cells were grown on 
irradiated mouse embryonic fibroblasts (MEFs), fed daily with iPSC/hESC media, and manually 
passaged every six to seven days. iPSC/hESC media consisted of DMEM/F12 supplemented 
with knock-out serum replacement (KOSR), L-glutamine plus β-mercaptoethanol, non-essential 
amino acids (NEAA), and 2x basic FGF. All cells were grown in a humid incubator kept at 37°C 
and 5% CO2.  
Materials for CRISPR/Cas9-mediated genome editing 
The sgRNA used to edit the Rx35i-7 iPSC line and the sgRNA located at the 3’ end of 
UBE3A used to delete UBE3A in H9 hESCs were both designed by Chris Stoddard of the 
hESC/iPSC Targeting Core at the University of Connecticut Health Center. The sgRNA used in 
the Rx35i-7 iPSCs was designed to preferentially target the maternal UBE3A allele, which 
contained the AS-causing point mutation in these iPSCs. The core also designed and 
constructed a targeting vector used in the initial attempts to edit this cell line (Figure 1A). The 3’ 
UBE3A gRNA targets the last exon of the gene, just upstream of the STOP codon (Figure 5). 
All other sgRNAs and all single-stranded oligonucleotides (ssODNs) were designed by the 
author. These sgRNAs were designed using MIT’s CRISPR design website 
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(http://crispr.mit.edu). Three sgRNAs were designed to target the translational start sites of the 
UBE3A protein isoforms, with one sgRNA designed per isoform/start site (Figure 4).  
All sgRNAs were cloned into the plentiCRISPRv280 (AS Pt Mut iPSCs), pX33081 (AS Pt 
Mut iPSCs; UBE3A deletion 3’ CRISPR), or pX459v282 (all other lines) vectors, which also 
contain human codon-optimized SpCas9 and puromycin resistance cassette. Design of ssODNs 
was based on work from Yang et al (2013).83 Each ssODN contained the intended correction or 
mutation of the UBE3A gene, as well as a silent mutation to create a restriction digest site. This 
site was introduced to facilitate the screening of a large number of clones, as well as to disrupt 
the PAM sequence, which would prevent Cas9 from re-cutting an edited allele. For all silent 
mutations, the codons used were confirmed to be ones already used elsewhere in the gene. 
This ensured that the cell already had the appropriate transfer RNA (tRNA) for that codon, 
which could then be used during translation. The ssODNs used to generate the Isoform 2 and 
Isoform 3 KO lines were ordered as the reverse compliment to the strand containing the PAM 
sequence and the 5’ ends phosphorylated. All sgRNAs and ssODNs are shown in Tables 1 & 2. 
Electroporation or Nucleofection of iPSCs/hESCs 
 Stem cells were incubated in 10 μM ROCK inhibitor (ROCKi, Y-27632) for 6 to 24 hours 
prior to electroporation. Cells were singlized using Accutase, pelleted by centrifugation, then 
resuspended in cold PBS. Resuspended cells were loaded into a cuvette containing 10 μg 
CRISPR vector and, when appropriate, 2-6 μl of 100 μM ssODN, then electroporated using the 
Gene Pulser X Cell (BioRad). Electroporated cells were centrifuged to remove cell debris then 
plated onto a 10 cm DR4-MEF dish in media containing ROCKi and the small molecule 
L755507 (5 μM; Xcessbio), which was reported to enhance homology directed repair (HDR)84. 
For some experiments, when relevant, the small molecule SCR7 was also added to the media 
as it had been reported to block NHEJ.85 Puromycin selection was started 24 hours after 
electroporation and maintained for 48 hours. L755507, SCR7 and ROCKi were removed from 
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the media 48 hours after electroporation. Cells were then maintained in regular iPSC/hESC 
media until large enough to screen, at which point they were put into ROCKi and 
penicillin/streptomycin overnight prior to screening. Electroporation was used to generate the 
following cell lines: correction of AS Pt Mut iPSCs (Corrected iPSC line), knockout of UBE3A in 
MCH2-10 iPSCs (MCH2-10ΔU line), and mutation of the isoform 1 translational start site in H9 
hESCs (Iso1KO line). For correction of the AS Pt Mut line, early attempts to correct the UBE3A 
mutation were done by electroporating the CRISPR (10 μg) and a targeting vector (40 μg) 
containing a floxed neomycin resistance cassette. These cells were selected with G418 (50 
μg/mL) starting 72 hours after electroporation and maintained in G418 for 5 days. 
Cells edited by nucleofection were treated similarly to electroporated cells with the 
following changes: singlized stem cells were resuspended in a solution containing nucleofector 
solution, supplement solution, 2 μg of CRISPR vector and 3 μl of 100 μM ssODN (Iso2KO and 
Iso3 KO lines), or 2.5 μg of each CRISPR vector (ΔUBE3Am-/p+ and UBE3A KO lines). 
Resuspended cells were loaded into a cuvette and nucleofected using the Amaxa 4D 
Nucleofector (Lonza). Nucleofection was used to generate the following cell lines: mutation of 
isoform 2 translational start site (Iso2KO line), mutation of isoform 3 translational start site (Iso3 
KO line), and deletion of UBE3A in H9s (ΔUBE3Am-/p+ and UBE3A KO lines). For each 
electroporation, 6-8 x 106 cells (3 wells of a 6 well plate) were used, while for each nucleofection 
2-3x106 cells (1 well of a 6 well plate) were used.  
Clone Screening 
 Individual colonies were cut into pieces using sterile needles, then half of the colony 
transferred into a well of a round-bottom 96 well plate containing stem cell media, ROCKi, and 
pen/strep. The other half of each colony was harvested for HotSHOT (hot sodium hydroxide and 
tris) genomic DNA (gDNA) preparation. Cells were pelleted by spinning in a tabletop centrifuge 
for 30 to 60 seconds. Cell culture medium was removed then the pellet incubated in 25 μl of 
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alkaline lysis reagent (25 mM NaOH, 0.2 mM EDTA) for 45 minutes at 95°C. Next 25 μl of 
neutralization reagent (40 mM Tris-HCl) was added, then the tubes were mixed by vortexing (2-
3 brief pulses). Resulting HotSHOT gDNA was immediately used in conventional PCR reactions 
specific to each genome editing experiment (see Results section). At the end of the clone 
screening process, positive clones were transferred from round bottom wells into individual 
wells of a 12 or 24 well MEF plate and kept in ROCKi and pen/strep overnight. 
Conventional PCR 
 Conventional PCR reactions were performed using either Herculase II Fusion DNA 
Polymerase (Agilent) or Platinum Taq DNA Polymerase High Fidelity (ThermoFisher). Primers 
used for each genome editing experiment are listed in Table 4. 
Stand-specific RT-PCR 
Strand-specific RT for the UBE3A-ATS transcript was performed on 1 μg of DNase I-
treated RNA isolated from 10-week-old H9 hESC-derived neurons using Superscript III Reverse 
Transcriptase (ThermoFisher Scientific). RT was performed according to manufacturer’s 
instructions with the following exception: the 60-minute incubation was done at 53°C instead of 
55°C, as recommended for gene-specific primers. RT-PCR was performed on the stand-specific 
cDNA libraries using the Advantage 2 Polymerase PCR Kit (Takara Bio). PCR reactions were 
prepared using the 10X Advantage SA Buffer and run on a thermal cycler set at 94°C/3min; 
[94°C/15sec, 60°C/30sec, 68°C/30sec] x 32 cycles; 72°C/10min. Primers used for RT and RT-
PCR are listed in Table 4.  
Western Blot 
 Western blot to confirm knockdown of UBE3A in the MCH2-10ΔU line was performed as 
described in Fink et al (2017).76 Briefly, cells were lysed using PathScan Lysis Buffer (Cell 
Signaling Technology) supplemented with 1 mM phenylmethane sulfonyl fluoride (PMSF; Gibco) 
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and Protease Inhibitor Cocktail III (used at 1:200; Calbiochem (EMD Millipore)). Fourteen 
micrograms of total cell lysate were separated by SDS-PAGE using 4-20% TGX Stain-Free mini 
gels (BioRad). Protein was transferred to PVDF membranes using the TransBlot Turbo system 
(BioRad). Membranes were blocked in 5% milk in TBS-T (Tris-buffered saline plus 0.1% Tween-
20) for 1 hour at room temperature then incubated in blocking buffer containing primary 
antibodies overnight at 4°C (UBE3A) or at room temperature for an hour (GAPDH). Membranes 
were washed with TBS-T at room temperature, incubated in blocking buffer containing HRP-
conjugated secondary antibodies for 1 hour at room temperature, then washed again in TBS-T. 
Membranes were imaged using the Clarity Western ECL substrate (BioRad) on the ChemiDoc 
Touch Imaging System (BioRad). The following primary antibodies were used: rabbit anti-
UBE3A (Bethyl Laboratories Inc., 1:1000), mouse anti-GAPDH (EMD Millipore, 1:10,000). 
Secondary antibodies (Cell Signaling Technologies) were used at the following concentrations: 
anti-rabbit-HRP 1:3000, anti-mouse-HRP 1:10,000 
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Results 
Correction of UBE3A point mutation in AS iPSCs 
A. Correction of mutation using CRISPR + targeting vector 
AS Pt Mut iPSCs were electroporated with pX330 vector containing a sgRNA specific to 
the mutant allele and targeting vector containing the wild type UBE3A sequence to use as a 
template for HDR. Four clones survived 5 days of selection with G418 and no additional 
colonies appeared after switching the plate to regular media for an additional 8 days. The 
four clones were expanded and genomic DNA isolated. Clones were screened by 
conventional PCR with primers within and outside of the targeting vector homology arms 
(Figure 1B and Table 4). One clone (#1) was positive and sent out for Sanger sequencing 
to determine whether the mutation was corrected. Sanger sequencing revealed correction of 
the mutation in this line and the presence of a silent mutation introduced to identify the 
edited allele in downstream applications (Figure 1C). Clone 1 was then nucleofected with 
CRE-IRES-Puro plasmid to remove the floxed Neo cassette that should have been inserted 
during the electroporation. All clones screened did not have any loxP sites present following 
nucleofection even though one loxP would be expected to remain following CRE-mediate 
recombination (Figure 1D). It is likely that the 5’ arm of the targeting vector was not 
integrated during the genome editing process and only the 3’ end (downstream of the Neo 
cassette) was used as a template for HDR. Ultimately, this cell line was not used for any 
further work as it was determined that this stem cell line was not the one derived from the 
AS patient but from the patient’s mother.  
B. Correction of mutation using CRISPR + ssODN 
AS Pt Mut iPSCs were corrected to a wildtype genotype by electroporation of cells with 
plentiCRISPRv2 vector containing the same sgRNA as above and an ssODN. This ssODN 
contained both the wildtype sequence for the region of interest in the UBE3A gene (to 
27 
 
correct the AS mutation) and a silent mutation that created a FokI restriction site (Figure 2A 
and Table 2). Sixty-four clones were screened by conventional PCR of HotSHOT gDNA, 
followed by FokI digest of the PCR product. Clones with a positive digest were expanded 
then their genotype confirmed by Sanger sequencing of PCR products off of phenol 
chloroform-extracted gDNA to determine whether the AS mutation had been corrected. The 
first electroporation did not yield any positive clones out of the 40 screened, while the 
second electroporation yielded one clone (#22) out of 64 that had digested and that, upon 
sequencing, had both the silent mutation and correction of the point mutation (Corrected 
line; Figure 2C). Both the AS Pt Mut and Corrected iPSC lines were used for the work 
detailed in Chapter 3 of this thesis.  
Mutate translational start sites for UBE3A protein isoforms in H9 hESCs 
Each UBE3A protein isoform is translated from its own unique translational start site, 
however the methionine used as the translational start site for Isoform 1 is present in the other 
two UBE3A isoforms (Figure 3A).47,48 Using CRISPR to create an indel at this location would 
therefore disrupt the reading frame of all three protein isoforms. For this reason, we chose to 
change the translational start sites of each protein isoform from a methionine to a leucine, which 
would prevent the methionine from being used as a start site. Replacing the methionine that 
serves as the Isoform 1 translational start site with a leucine was predicted to not cause any 
deleterious changes to the structure or folding of the remaining two UBE3A protein isoforms 
when analyzed with multiple protein prediction softwares (Figure 3B-C).86,87 The sgRNAs and 
ssODNs used to generate the three isoform knockout hESC lines are shown in Tables 1 & 2. 
The ssODNs contained sequences to change the appropriate methionine codon (ATG) into a 
leucine codon, as well as a silent mutation to create a restriction digest site and disrupt the 
PAM, which would prevent cutting of the edited allele(s). Clones were screened by conventional 
PCR of HotSHOT gDNA followed by restriction digest of the PCR product with TaqI (Isoform 1 
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KO), HindIII (Isoform 2 KO), or HPYCH4V (Isoform 3 KO). Digest positive clones were then 
sequenced by Sanger sequencing. Using this method, we were able to identify one 
homozygous clone for each of the three isoform start sites in which the methionine codon had 
been changed to a leucine codon, resulting in three edited hESC lines (Clone #15 (Iso1), #60 
(Iso2), and #77 (Iso3); Figure 4B-D). To obtain these lines, two, four, and four rounds of 
electroporation or nucleofection were performed to mutate Isoform 1, 2, and 3, respectively. The 
Isoform 1 KO clone was originally a mixed clone with some cells possessing the wildtype 
sequence and silent mutation but the majority of the cells possessing only the start site 
mutation. Upon routine passaging to maintain the cell line, the small population of silent 
mutation + wildtype start site cells was eventually removed (Figure 4B). The isoform KO lines 
were used in work detailed in Chapter 4 of this thesis. 
Deletion of UBE3A in H9 hESCs 
To generate an additional pair of isogenic AS and control stem cells, we deleted the 
maternal copy of UBE3A in H9 hESCs. To do this, we employed the strategy described by Kraft 
and colleagues, where a pair of CRISPRs flanking a region of interest was used to generate 
clones with deletions, duplications, and/or inversions of that region.88 To delete UBE3A, we 
used the isoform 1 translational start site CRISPR described above (located at the 5’ end of the 
gene) and a CRISPR located at the 3’ end of the gene just upstream of the STOP codon, which 
had been previously used by our lab to insert a GFP into the UBE3A gene (Figure 5A). Clones 
were screened for the presence of deletions, duplications, or inversions using different 
combinations of primers (Figure 5A-C and Table 3). Clones identified by PCR as being 
heterozygous for a deletion of UBE3A were Sanger sequenced to determine whether were any 
indels on the intact allele (Figure 5D), as both CRISPRs are located in exons. Using this 
method, we were able to identify one clone with a maternal deletion of UBE3A (#28; ΔUBE3Am-
/p+) and multiple clones with both alleles of UBE3A either deleted or mutated, resulting in 
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homozygous knockouts (UBE3A KO). While homozygous KO clones were identified during 
every round of genome editing, no clean heterozygous clones were identified until the 5th round 
of genome editing. The H9ΔUm-/p+ line was used in work detailed in Chapter 3 of this thesis, 
while one of the UBE3A KO clones was used as a control line for experiments detailed in 
Chapter 4. 
To determine the identity of the deleted allele in the heterozygous deletion clone, we 
took advantage of the presence of SNPs near the 5’ CRISPR cut site (Figure 6A). Sanger 
sequencing of H9 hESC gDNA confirmed the presence of 4 SNPs within 3.1 kb of this location 
(Figure 6B). Strand-specific RT-PCR (ssRT-PCR) was performed to determine the allelic 
identity of each SNP. To do this, we used RNA from H9 10-week neurons in order to sequence 
the UBE3A-ATS, as it is produced exclusively from the paternal allele in neurons and is 
complimentary to the gDNA of the paternal copy of the gene. In order to sequence these 
specific SNPs, primers complementary to the UBE3A-ATS at regions near the SNPs of interest 
were used in the ssRT reaction. ssRT-PCR products were then Sanger sequenced to identify 
the SNPs (Figure 6C). Because rs1041933 had the cleanest sequencing trace, we used that 
SNP to determine which allele was deleted in our heterozygous clone. Conventional PCR was 
first performed to amplify the intact allele, then a nested PCR using primers located near the 
SNP were used on the gel-purified product of the first reaction. Finally, the second product was 
sent for Sanger sequencing. The presence of a G at this SNP indicated that the intact allele was 
the paternal copy of the chromosome (Figure 6D) and therefore the maternal allele was 
deleted. 
Knockout of UBE3A in normal iPSCs 
The Isoform 1 start site CRISPR was also used to generate a UBE3A knockout line in 
MCH2-10 normal iPSCs. iPSCs were electroporated with CRISPR plasmid in hopes that cutting 
by Cas9 would result in non-homologous end joining (NHEJ) and produce an indel that would 
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shift the reading frame for the protein. Since the methionine used as the isoform 1 start site is 
present in all three protein isoforms, an indel at this location would likely disrupt all three protein 
isoforms. The goal was to mutate both copies of UBE3A so as to avoid having to screen for 
clones with only the maternal copy of UBE3A mutated. Clones were screened by Sanger 
sequencing of the CRISPR cut site to check for indels. One clone (#33) had a one base pair 
insertion (Figure 7A) but appeared to be a mixed clone as the sequencing trace had low levels 
of wildtype sequence. TIDE analysis (Tracking of Indels by DEcomposition89) confirmed that at 
least 12% of the sample was still wildtype. This clone was singlized and subclones were 
resequenced and reanalyzed by TIDE, confirming the absence of wildtype gDNA (Figure 7B). 
Knockdown of UBE3A protein in the iPSCs was confirmed by Western blot (Figure 7C). These 
stem cells were differentiated into neurons and used to determine whether the UBE3A KO 
neurons recapitulated electrophysiological phenotypes seen in AS iPSC-derived neurons when 
compared to their isogenic control.76  
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Discussion 
 This chapter demonstrates the successful generation of isogenic stem cell lines using 
CRISPR/Cas9-mediated genome editing. Generation of these stem cell lines was necessary for 
the experiments outlined in the next two chapters and have also been critical components of 
experiments done in the labs of collaborators to establish robust cellular phenotypes in AS 
neurons. As discussed in Chapter 3, the AS Pt Mut/Corrected and H9/ΔUBE3Am-/p+ lines were 
used to establish a molecular transcriptome phenotype for AS stem cell derived neurons, while 
in Chapter 4, the Isoform KO lines were used to examine the abundance and localization of the 
UBE3A isoforms. The MCH2-10ΔU iPSCs was used to confirm that electrophysiological 
phenotypes seen in AS iPSC-derived neurons were a direct result of UBE3A deficiency.76 These 
iPSCS, as well as the AS Pt Mut/Corrected iPSCs, and ΔUBE3Am-/p+ hESC lines are currently 
being used to study the morphology of cultured AS stem cell-derived neurons. Furthermore, the 
AS Pt Mut/Corrected and MCH2-10/MCH2-10ΔU lines are available for distribution to other 
institutions, where they can be used to ask other questions relevant to AS research. In addition 
to the above applications, there are many other potential applications of these stem cell lines. 
As seen in Chapter 4, the UBE3AKO line makes an excellent negative control for antibody-
based applications such as immunocytochemistry, Western blot, or ChIP-seq. Having isogenic 
AS and control pairs will be useful in establishing other phenotypes for stem cell-derived AS 
neurons, but also could be serve as a negative control in proteomics approaches to identify 
putative neuronal targets of UBE3A.  
 As demonstrated above, genome editing experiments that rely on HDR to make specific 
changes to the genome are relatively variable in their efficiency. As CRISPR is still a relatively 
new technology, the field is constantly changing and improving the methods used to conduct 
these experiments. Indeed, during the course of the work described above, multiple changes 
were made to the way we designed our oligos and performed genome editing experiments. For 
32 
 
example, we found that delivery of the CRISPR plasmid and ssODN via nucleofection appeared 
to improve the number of positive clones identified during clone screening. The use of ssODNs 
as a template for HDR was also a major change, since previously all work had been done using 
targeting vectors, as in Figure 1. We also began to phosphorylate the 5’ ends of the ssODNs. 
Finally, multiple small molecules were published that purported to either enhance HDR (such as 
L75550784) or inhibit NHEJ (such as SCR785), both of which were used when appropriate. 
 Even with these improvements, however, these experiments were still relatively 
inefficient, especially the mutations of the Isoform 2 and 3 start sites. Future attempts at HDR 
could make one or more of the following changes in an attempt to further improve efficiency. To 
generate cell lines with heterozygous corrections or mutations without indels on the other allele, 
one approach is to use two ssODNs containing a silent mutation – one with the WT sequence 
and one with the intended edit. In this case, Cas9 has generated a double-stranded break on 
both alleles and both ssODNs are used as templates for HDR.90 During the process of 
screening clones, we encountered multiple instances of putatively positive clones that digested 
during screening that would also have indels, which were only revealed upon Sanger 
sequencing. Positive clones identified using the double ssODN method would be less likely to 
have indels on the wildtype allele. In the case of the isoform mutation cell lines above, if it had 
been necessary to have heterozygous start site mutations on the maternal allele, this method 
could have been employed to decrease the likelihood of finding clones with indels. While we 
were fortunate to be able to use ssODNs as templates for HDR to generate our final cell lines, 
there are certain situations that necessitate the use of a targeting vector as the template for 
HDR. For example, fluorescent proteins are too large to insert using an ssODN. Recently, it was 
shown that altering the design of the targeting vector so that the homology arms are flanked by 
sgRNA+PAM sequences improved the efficiency of HDR in both HEK293T cells and iPSCs. 
This efficiency was also further improved by treating cells with small molecules shown to 
regulate the cell cycle.91 
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 In summary, we have used the CRISPR/Cas9 system to perform various genome edits 
to the UBE3A genomic sequence, generating isogenic stem cell lines. These isogenic lines 
have been used to establish robust cellular models for studying AS and UBE3A, and for 
establishing and validating several AS in vitro phenotypes.  
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Figure 1. Correction of AS point mutation using CRISPR and targeting vector 
A Top: location of proposed genome editing in UBE3A gene. sgRNA = location of sgRNA used 
to correct mutation. Bottom: schematic illustrating proposed genome editing using a targeting 
vector as the template for HDR. Inset: Sanger sequencing of iPSCs containing point mutation. B 
Top: schematic illustrating correctly targeted allele and PCR primers used for screening 
clones… (continued on next page) 
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Bottom: Agarose gel images showing PCR products in clones screened. C Sanger sequencing 
of clone 1 showing correction of point mutation D Top: schematic illustrating correctly targeted 
clone following Cre-mediated recombination and removal of Neo cassette; Bottom: Agarose gel 
image showing PCR products in clones screening following nucleofection with Cre-expressing 
plasmid.  
 
Scissors = Cas9 cut site; yellow star = location of point mutation; blue box = exon; grey line = 
intron; solid line/box = region used for homology in targeting vector; dashed line = genomic 
sequence outside of homology region; yellow triangle = loxP; Neo = neomycin resistance 
cassette; PGK = promoter; DTA = diptheria toxin A; arrow = primer location; + = positive control; 
- = no template control; * = expected product size 
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Figure 2. Correction of AS point mutation using CRISPR and ssODN 
A Schematic showing proposed genome editing in UBE3A gene and sequence of ssODN used 
as template for HDR. sgRNA = location of sgRNA used to correct mutation. Inset: Sanger 
sequencing of AS point mutation in patient-derived iPSCs B Schematic showing timeline for 
genome editing experiments. C Top left: schematic showing locations of primers in targeted 
clone. Orange line indicates location of silent mutation, arrows indicate primers. Top right: 
Agarose gel image showing digested PCR products from clone screen following FokI digest. 
Bottom: Sanger sequencing of clone 22 showing correction of point mutation. 
Yellow star = point mutation location; orange star = location of silent mutation 
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Figure 3. Predicted effects of proposed mutation at isoform 1 translation start site on 
protein structure of isoforms 2 and 3 … (continued on next page) 
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A Top: Location of isoform translational start sites. Bottom: Amino acid sequence of isoform N-
termini. Red letters indicate common amino acids between the three isoforms. M indicates 
methionine used as translational start site. B & C Effect of proposed amino acid change on 
isoform 2 (B) and isoform 3 (C) protein. Top: results from Predict Protein software showing 
effects of every possible amino acid substitution of the methionine. Bottom: results from Predict 
SNP software showing predicted effects of L to M substitution from 7 different structure 
prediction algorithms. 
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Figure 4. Generation of isoform-null hESC lines 
A Schematic illustrating proposed genome edits at each isoform translational start site. Grey 
line = intron; blue box = exon; … (continued on next page) 
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green box = methionine used as start site; scissors = Cas9 cut site; arrows = primers used for 
screening B Generation of isoform 1-null line. Top: agarose gel image showing TaqI restriction 
digest of PCR products from clones. Bottom left: Sanger sequencing of clone 15 indicated that it 
was a mixed clone (arrows). Bottom left: Sanger sequencing of clone 15 after routine passage 
showing absence of WT sequence and presence of homozygous start site mutation (A to T). 
C Generation of isoform 2-null line. Left: agarose gel image showing HindIII restriction digest of 
PCR products from clones. Right: Sanger sequencing of clone 60 showing homozygous silent 
mutation and translational start site mutation. D Generation of isoform 3-null line. Left: agarose 
gel image showing HPYCHV restriction digest of PCR products from clones. Right: Sanger 
sequencing of clone 77 showing homozygous silent mutation and translational start site 
mutation. 
 
*  = clone used for cell line and clone shown in Sanger sequence trace; P = parent line (H9 
hESCs); + = positive control for restriction digest; red arrow = undigested PCR product; blue 
arrows = digested PCR product; black arrows = edited nucleotides 
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Figure 5. Generation of UBE3A deletion in hESCs 
A Schematic illustrating proposed genome editing. Scissors = Cas9 cut sites. Arrows = locations 
of primers used for screening clones B Agarose gel images showing PCR products from 
indicated primer combinations. Top: primers spanning the deletion region: positive product 
indicates deletion occurred on at least one allele Bottom: primers located within deleted region: 
positive product indicates at least one copy of UBE3A is intact. Green arrow shows a clone with 
a homozygous deletion, blue arrow shows a clone with a heterozygous deletion C 
Characterization of heterozygous clone via various combinations of primers (explained in Table 
3). * = heterozygous clone; P = parent line; - = no template control D Sanger sequencing of 
heterozygous clones showing no mutations at the CRISPR cut sites on the intact allele. 
Scissors indicate Cas9 cutting location. Red line indicates PAM (NGG). Black line indicates 
sgRNA binding location. Left: cut site at 5’ end of UBE3A gene. Right: cut site at 3’ end of 
UBE3A gene. The stop codon is highlighted in blue. 
  
42 
 
 
 
Figure 6. Determining the identities of the deleted and intact alleles 
A Location of SNPs relative to 5’ CRISPR cut site. B Sanger sequencing of genomic DNA from 
H9 hESC showing presence of 4 SNPs. C Sanger sequencing of UBE3A-ATS transcript cDNA 
showing presence of 4 SNPs. Arrow indicates location of SNP. … (continued on next page) 
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D Top: schematic illustrating sequencing of deleted and intact alleles in heterozygous UBE3A 
deletion clone. Horizontal arrows indicate primer locations. Green and black segment indicates 
location of SNP. Middle: agarose gel images showing PCR amplification of non-deleted allele 
(left) followed by amplification around the SNP of interest (right). * = PCR product from 
heterozygous deletion clone; + = positive control; - = no template control; Bottom: Sanger 
sequencing showing identity of the SNP (vertical arrow). 
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Figure 7. UBE3A knockout in normal iPSCs 
A Sanger sequencing showing insertion of a G at CRISPR cut site (blue highlighted nucleotide) 
B TIDE analysis of clone after singlization showing no wildtype sequence and insertion of 1 bp 
C Western blot comparing parent iPSC line (NML1-0) to UBE3A KO iPSC line (NML1-0 
ΔUBE3A) D Editing of normal iPSCs did not affect pluripotency of iPSCs, as indicated by 
expression of multiple pluripotency markers. 
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Table 1. sgRNAs used to generate stem cell lines 
Cell Line/Project sgRNA sequence + PAM Vector 
Correct mutation in Rx35i-
7 iPSCs 
CCCTCAGTTTCAGAAGAAGATGG pX330 
Correct mutation in Rx35i-
7 iPSCs 
CCCTCAGTTTCAGAAGAAGATGG plentiCRISPRv2 
Isoform 1 start site mut. 
(H9); 
UBE3A KO in MCH2-10; 
UBE3A deletion (H9) 
CCGAATGTAAGTGTAACTTGGTT pX459v2 
Isoform 2 start site mut. 
(H9) 
AAAAGGAGTGGCTTGCAGGATGG pX459v2 
Isoform 3 start site mut. 
(H9) 
ATCACCCTGATGTCACCGAATGG pX459v2 
3’ CRISPR for UBE3A 
deletion (H9) 
AGGCCATCACGTATGCCAAAGG pX330 
 
Table 2. ssODNs used to generate stem cell lines 
Cell Line/Project ssODN sequence 
Correct mutation in 
Rx35i-7 iPSCs 
TGAATCTACAAAATTGTTTTGGTTTAATCCATCCTCTTTTGAAACT 
GAGGGTCAGTTTACTCTGATTGGC 
Isoform 1 start site 
mutation (H9) 
AGAACCTCAGTCTGACGACATTGAAGCTAGTCGATTGTAA 
GTGTAACTTGGTTGAGACTGTGGTTCTTAT 
Isoform 2 start site 
mutation (H9) 
ATTCAAATGGTGGCTCACTTCCAATAACACTGGTGAAGCTTCTCGA 
GCCTGCAAGCCACTCCTTTTACCTCCACTGTAACTCTCTAGGAGAG 
Isoform 3 start site 
mutation (H9) 
TGTAAAATAATTCAAAATTACCTTTTACAAGCTGTTGCAAGTCGGTG 
ACATCAGGGTGATCACAGCTTTGAGTCACTGATTAAAAA 
 
Table 3. Primer combinations used to screen UBE3A deletion clones 
Primer Set PCR Result Interpretation 
1 + 8 Presence of band indicates deletion of at least one allele 
6 + 7 Use to sequence 5’ cut site of intact allele to check for indels 
2 + 3 Use to sequence 3’ cut site of intact allele to check for indels 
3 + 7 Presence of band indicates inversion of intact allele (two forward primers) 
3 + 8 Presence of band indicates inversion of intact allele (two forward primers) 
4 + 5 Presence of band indicates presence of at least one intact allele / absence of 
band indicates a homozygous deletion 
2 + 6 Presence of band indicates inversion of intact allele (two reverse primers) 
3 + 6 Presence of band indicates a duplication of the intact allele 
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Table 4. Primer Sequences Used for Genome Editing 
Primer Name Letter/Number in Fig. Sequence 
EndogR2 A TTGGAATTTTATCACCATTTTCCA 
EndogR1 B GATCATCATGTCATCTTCCACATT 
OrigR C TTTTCCCCATTAGCTTCCT 
OrigSeqF D AGGTATGTTCACATACGATG 
OrigF E TTCATCAGTCCTTAATAAAATACAAAA 
ExogF2 F ACGAAGTTATTAGGTCCCTCG 
EndogF2 G CAACTACTCCGGAGGCTGAG 
EndogF1 H GGATTACAGGTGTGAACTACCACA 
EnNeoR I / 4 GCACTTGAGAAAACAATGTCCA 
EnNeoF J / 5 TGAAACACTTTGGAAATGTAGCC 
NewR K TTATTGTAAATAGCCAGACCCAGT 
Iso1R L / 6 CTGCTACCAGGGAAGCAAAA 
Iso1SeqF M TTCTTTCATGTTGACATCTTTAATTTT 
Iso1F N / 7 GCTTATAATGGCTTGTCTGTTGG 
Iso2R O TGAAACAATAACCAAATAACATTGG 
Iso2SeqR P TCTTGATTTGAATCGCAGAAAA 
Iso2F Q TCAGTAGCCACTATCAAAGACCT 
Iso3R R TTTTTGAACAATGAATTGGGTTT 
Iso3SeqF S AGCCTACGCTCAGATCAAGG 
Iso3F T TTTTTGAACAATGAATTGGGTTT 
UBE3A_del_F1 1 AGTCCAACCCTTAAAATAAATGTG 
UBE3A 3’ R 2 TGGGACACTATCACCACCAA 
UBE3A_intron12_F1 3 GGCAACTTGGTAGTTACACAACA 
UBE3A_del_R1 8 CCCACATGTCCCCAATAAAG 
SNP-933 R 9 AAAATTAAGCAGCCTCCGAGT 
SNP-933 F 10; Also used for ssRT TTAAGCAGTTGCCCTCCTTG 
Primers also used but not shown in any figures: 
UBE3A_intron12_F2  seq 3’ cut site  CCCATGACTTACAGTTTTCCTG 
SNP-933 seq  seq SNP  TGACTGAATTTGTCCGTATTTGA 
SNP-1038 F Also used for ssRT GCAGTGGCACCTTCTTGACT 
SNP-1038 R  GAGCTGTCATGGATAAACAAGC 
SNP-1038 seq seq SNP CCTCTCTTCCAGTCCCCTCT 
SNP-726 F Also used for ssRT TTCACAGCCTCTGACAACCA 
SNP-726 R  CACAATATGTGATGGCAAGGA 
SNP-726 seq seq SNP GCTCTGGAAGAGTATGGCAGT 
SNP-529 F Also used for ssRT TGCAGAACAAGGGTCCAAAC 
SNP-529 R  GGTGTCACGTTTCCCTGACT 
SNP-529 seq seq SNP ACACTGGTCCTTGCAGATCC 
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Abstract 
Angelman Syndrome (AS) is a neurodevelopmental disorder occurring approximately once in 
every 15,000 live births, characterized by severe seizures, absent speech, motor dysfunction, 
profound intellectual disability, and happy demeanor. Loss of expression of the maternal copy of 
UBE3A, a gene regulated by tissue-specific genomic imprinting, causes AS. UBE3A encodes an 
E3 ubiquitin ligase that may also act as a transcriptional co-activator. Although there is currently 
no cure, multiple therapies for AS, including gene therapy, are currently being explored. It will 
therefore be necessary to test the efficacy of these therapies in human AS neurons. Here, we 
have used isogenic AS and control stem cell-derived neurons to establish a molecular 
transcriptome phenotype for AS. We have generated two AS/control isogenic stem cell line 
pairs. First, we have derived induced pluripotent stem cells (iPSCs) from an AS patient with a 
missense mutation in UBE3A (AS Pt Mut). This mutation does not affect UBE3A RNA or protein 
levels but causes a reduction in the protein’s ubiquitin ligase activity, as demonstrated by in vitro 
ubiquitination assays. Using CRISPR/Cas9-mediated genome editing, we have corrected this 
point mutation in the AS Pt Mut iPSCs, generating an isogenic control iPSC line (Corrected). 
Second, we have used CRISPR/Cas9 to delete the maternal copy of UBE3A in H9 human 
embryonic stem cells (hESCs). Both isogenic pairs of stem cells were then successfully 
differentiated into forebrain neurons. Whole-cell patch-clamp recordings were performed on 12-
week neurons to determine the extent to which the AS stem cell-derived neurons recapitulate 
the electrophysiological phenotypes seen in other non-isogenic AS iPSC-derived neuron lines. 
Stand-specific mRNAseq was then performed on all 4 neuron lines to find a list of common 
genes differentially expressed in AS neurons (n = 855, p < 0.01). Lastly, we tested the ability to 
rescue electrical and molecular phenotypes by treating AS Pt Mut and Corrected neural 
progenitors with lentivirus encoding E6 oncoprotein, which restores ubiquitin ligase function to 
the mutant version of UBE3A in in vitro ubiquitination assays. Expression of E6 in point mutation 
neurons was able to rescue both the resting membrane potential electrical phenotype as well as 
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restore expression of multiple genes identified by mRNAseq. These results demonstrate that the 
transcriptome phenotype is a useful tool assaying phenotypic restoration in stem-cell derived 
neurons, and also suggest that allosteric activation of UBE3A may be a useful mechanism to 
explore for potential AS therapies. 
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Introduction 
 Chromosome 15q11-q13 is regulated by genomic imprinting, an epigenetic phenomenon 
that results in the differential expression of genes in a parent of origin-specific manner.1 The 
UBE3A gene found in this region undergoes tissue-specific imprinting: it is expressed 
biallelically in non-neuronal cells, but is silenced on the paternal allele in neurons due to the 
expression of a long-noncoding RNA, the UBE3A-antisense (UBE3A-ATS).11 Subsequently, 
mutations or deletions affecting the maternal copy of UBE3A result in a loss of UBE3A in 
neurons, which causes Angelman Syndrome (AS).21 AS is a rare neurodevelopmental disorder 
that occurs in 1 in 15,000 live births, and is characterized by severe seizures, ataxia, happy 
affect, absent speech, and intellectual disability.20 Although there is no cure for AS, several 
promising approaches to restore UBE3A expression are currently being explored as potential 
AS therapies. Unsilencing the paternal copy of UBE3A, using either topoisomerase inhibitors or 
antisense oligonucleotides, has been demonstrated in in vitro and in vivo studies, and was 
shown restore some phenotypes in adult AS mice.65,70 Viral vector-based gene therapy to 
replace the UBE3A gene product is also being explored.71,72 While demonstrating the safety and 
efficacy of these approaches in mice is important, it is also necessary to test these potential 
therapies in human cells, specifically human neurons, not only to assess their toxicity but to 
assess the relative effectiveness of therapies that are specific to the human genomic sequence.  
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), which can be 
differentiated into neurons, provide us with the unique opportunity to test these potential 
therapies on human neurons in vitro. In order to do so, however, it is necessary to first establish 
robust in vitro AS phenotypes that can be assayed following treatment of neurons with potential 
therapeutics. Previously, we showed that AS iPSC-derived neurons exhibit a phenotype of 
impaired electrophysiological maturation.76 Here, we have used CRISPR/Cas9 to generate two 
pairs of isogenic AS and control human pluripotent stem cells. We established a quantitative 
molecular phenotype for AS neurons by performing mRNAseq on two pairs of isogenic AS and 
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control stem cell-derived neurons. Using conservative criteria, we have identified a list of genes 
that are consistently differentially expressed in AS that can serve as a molecular phenotype for 
human stem cell-derived AS neurons. We validated the use of these genes as a molecular 
phenotype by assaying their expression following restoration of UBE3A function in neurons 
differentiated from AS iPSCs. We propose that this list of genes can be used as a tool to assess 
the efficacy of potential AS treatments when testing them on cultured human AS neurons. 
These genes can be assayed in a relatively high-throughput manner, making the transcriptome 
an ideal phenotype for screening potential AS therapeutics. 
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Methods 
Patient-Specific Fibroblasts & Generation of iPSCs  
Fibroblasts were obtained from a skin punch biopsy following appropriate informed consent from 
a 7-year old male with Angelman syndrome. This boy carried a C to T transition resulting in a 
phenylalanine to serine missense mutation in the maternally-inherited copy of his UBE3A gene.  
The parent of origin of the mutation was known because the mother and maternal grandfather of 
the boy both carried the same mutation. iPSCs were derived by the UConn-Wesleyan Stem Cell 
Core (Farmington, CT) from patient fibroblasts using the human polycistronic STEMCCA 
lentiviral vector encoding OCT4, KLF4, SOX2, and CMYC,92 as previously described.93 
iPSC/hESC culture and neuronal differentiation 
iPSCs and hESCs were cultured on irradiated mouse embryonic fibroblasts (irrMEFs) and fed 
daily with SC media consisting of DMEM/F12 containing knockout serum replacement, L-
glutamine + β-mercaptoethanol, non-essential amino acids (NEAA), and basic fibroblast growth 
factor. SCs were manually passaged every 5-7 days and cultured at 37°C in a humid incubator 
at 5% CO2.78  
SCs were differentiated into neurons using a modified version of the monolayer differentiation 
protocol.79,94 Two days after passaging, SCs were cultured in N2B27 medium (Neurobasal 
medium, 1% N2, 2% B27, 2 mM L-glutamine, 0.5% penicillin/streptomycin, 1% insulin-
transferrin-selenium). N2B27 medium was supplemented with fresh Noggin (500 ng/mL) for the 
first 10 days of differentiation. Approximately 2 weeks after beginning differentiation, neural 
rosettes were passaged onto poly-ornathine and laminin-coated plates using the StemPro EZ 
Passage tool (Thermo Fisher). Neural progenitors were replated at a high density around 3 
weeks of differentiation, switched to neural differentiation medium (NDM) around 4 weeks of 
differentiation, then plated for terminal differentiation around 5 weeks. NDM consisted of 
neurobasal medium, 1% B27, 2 mM L-glutamine, 0.5% pen-strep, non-essential amino acids, 1 
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μM ascorbic acid, 200 μM cyclic AMP, 10 ng/mL brain-derived neurotrophic factor, and 10 
ng/mL glial-derived neurotrophic factor. Neurons were maintained in culture until 10 to 12 weeks 
of differentiation. 
CRISPR/Cas9-mediated genome editing 
sgRNAs were designed using MIT’s CRISPR Design Tool (http://crispr.mit.edu) and cloned into 
either plentiCRISPRv2 (Addgene 52961) or pX459v2.0 (Addgene 62988) vector, as previously 
described.95,96 The sgRNA used to correct AS Pt Mut iPSCs and the 3’ gRNA used to delete 
UBE3A in hESCs were designed by the hESC/iPSC Targeting Core at the University of 
Connecticut Health Center. Prior to electroporation or nucleofection, SCs were treated with 
ROCK inhibitor (Y-27632; Selleck Chemicals) for 24 hours. SCs were then singlized using 
Accutase (Millipore) and electroporated using the Gene Pulser X Cell (BioRad) or nucleofected 
using the Amaxa 4D Nucleofector (Lonza). For generation of the Corrected line, iPSCs were 
electroporated in PBS with 10 μg of CRISPR plasmid and 8 μl of single-stranded oligonucleotide 
(ssODN) template. For generation of the ΔUBE3Am-/p+ line, hESCs were nucleofected with 2.5 
μg of each CRISPR using the P3 Primary Cell Kit L (Lonza). SCs were then plated onto 
puromycin-resistant (DR4) irrMEFs at low density, supplemented with ROCK inhibitor and 
L755507 (5 μM, Xcessbio), which has been shown to improve efficiency of homology directed 
repair.84 24 hours after plating, cells underwent selection for 48 hours with puromycin (0.5 – 1 
μg/ ml). Puromycin resistant colonies were screened by conventional PCR (UBE3A deletion) or 
conventional PCR followed by restriction digest (AS Pt Mut correction) approximately 11-14 
days after plating. Putative clones were plated onto regular irrMEFs and successful genome 
editing was confirmed by Sanger sequencing. 
Conventional PCR and Stand-specific RT-PCR 
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Conventional PCR was performed on genomic DNA using Herculase II Fusion DNA Polymerase 
(Agilent). Strand-specific RT using primers specific to the UBE3A-ATS transcript was performed 
on RNA isolated from 10-week-old H9 hESC-derived neurons using Superscript III Reverse 
Transcriptase (Thermo Fisher Scientific). RT-PCR was performed on the strand-specific cDNA 
libraries using Advantage 2 Polymerase (Clontech).97 
Karyotype and pluripotency analysis 
Normal karyotype of AS Pt Mut, Corrected, & ΔUBE3Am-/p+ SCs was confirmed by the Genetics 
and Genomic Division of the University of Connecticut-Wesleyan University Stem Cell Core 
(Supplemental Figures S1-S2). A minimum of five G-banded metaphase stem cells were 
examined from each cell line.  
Electrophysiology 
Neurons were plated onto glass coverslips between 5 and 6 weeks of differentiation. Whole-cell 
voltage and current clamp recordings of 11- to 13-week-old stem cell derived neurons were 
performed as previously described.76 Briefly, recordings were performed on individual coverslips 
in a recording chamber fixed to the stage of the microscope that was continuously perfused with 
oxygenated artificial cerebrospinal fluid. Neurons were identified based on their morphology 
when viewed on infrared differential interference contrast (DIC) video microscopy. Patch 
pipettes (3 to 5 Ω) were pulled from borosilicate glass capillaries and filled with internal solution 
containing KCl, K-gluconate, HEPES, phosphocreatine, EGTA, CaCl2, Na2-ATP, and Na-GTP. 
Input resistance (Ri) was noted throughout the recording period. The following criteria were 
used to exclude neurons from analysis: series resistance (Rs) > 50 MΩ at time of break-in, Ri 
changed by > 15% during recording, or Ri < 100 MΩ during recording. Resting membrane 
potential (RMP) was noted at break-in by injection of 0 current. RMP values were corrected for 
liquid junction potential offline. To elicit AP firing, cells were held in current clamp mode at 
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approximately -70 mV, followed by application of 500 ms current steps from -20 to +40 pA in 
intervals of 5 pA. To elicit inward and outward currents, cells were held in voltage-clamp mode 
at -70 mV, followed by application of 300 ms steps from -100 to +40 mV in 10 mV increments. 
Finally, spontaneous excitatory synaptic activity was monitored while in voltage-clamp mode by 
holding the cell at -70 mV. Offline analysis of data was done using Clampfit software. For E6 
experiments, recordings were performed as described above with the following changes: after 
identifying neurons by morphology in infrared DIC, cells were then viewed in the GFP channel to 
find neurons that expressed GFP. GFP+ neurons were confirmed using TurboSM 
(RedShirtImaging) at the following settings: exposure time 100 sec, number of frames 1000, 
camera gain Low. Following confirmation of GFP expression, recordings were then performed 
while viewing the cell in infrared DIC. 
RNA sequencing 
Total RNA was isolated from 6 biological replicates of 12-week-old neurons differentiated from 
AS Pt Mut iPSCs, Corrected iPSCs, H9 hESCs, and H9ΔUBE3Am-/p+ hESCs using RNA Bee 
(Amsbio). ASO-treated H9 neurons were collected at the end of treatment (approximately 10.5 
weeks of differentiation). mRNAseq libraries were prepared using the TruSeq Stranded mRNA 
Library Prep Kit (Illumina) per the manufacturer’s protocol. 500 ng of RNA was used as input for 
each sample. Libraries were sequenced using the NextSeq500 sequencer (Illumina). Fastq files 
were run through fastqc and visualized using MultiQC, which revealed adapter contamination in 
a handful of samples. All samples were run through Trimmomatic before proceeding with 
analysis. Reads were aligned to the human genome (GRCh37/hg19) and gene counts extracted 
using STAR. For AS Pt Mut, Corrected, H9, & ΔUBE3Am-/p+ neurons, at least 30 million reads 
were generated for each sample. For the ASO-treated H9 neurons, at least 18.4 million reads 
were generated for each sample. With the exception of one AS Pt Mut replicate (AS1; 74.82%), 
all samples had at least 84.24% uniquely mapped reads. Zero count genes and the bottom 10% 
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of genes with counts were removed, then counts normalized and transformed. Data was 
subjected to surrogate variable analysis98 then differential expression analyzed using DESeq2. 
For each analysis, an adjusted p-value (padj) of p<0.01 was used as a cut off for differential 
gene expression. Gene ontology analysis was performed using DAVID. Trimmomatic 
percentages, and alignment percentages can be found in Supplemental Table S3. Software 
versions can be found in Supplemental Table S4. 
Acute UBE3A knockdown experiment 
Ten-week-old neurons differentiated from H9 hESCs were treated for 72 hours with 10 μM of 
antisense oligonucleotide (ASO) against UBE3A or scramble control ASO. After treatment, 
neurons were harvested for RNA isolation. ASOs were provided by Ionis pharmaceuticals and 
have been described previously.76  
Site-directed mutagenesis of UBE3A cDNA for in vitro ubiquitination assay 
The AS-causing point mutation seen in the AS Pt Mut iPSCs was generated in UBE3A cDNA 
(c7-3)99 that had been cloned into pBluescript (SK-) plasmid. To generate a template containing 
the point mutation and restriction digest sites for ligation, sequential PCR reactions were 
performed off of the plasmid using restriction site-containing or mutation-containing primers. The 
PCR product and plasmid were digested with restriction enzymes, gel purified, then ligated. The 
resulting plasmid was transformed in DH10B chemically competent cells. Bacterial clones were 
screened by Sanger sequencing to confirm presence of the point mutation in the cDNA.    
In vitro ubiquitination assay 
Wildtype and mutated UBE3A cDNA were in vitro translated as previously described.41 To 
examine the auto-ubiquitination of UBE3A, baculovirus-expressed E1, E2 (UbcH7), and UBE3A 
were incubated in the presence or absence of ATP and/or E6 at 30°C for 90 min. The reaction 
mixture was electrophoresed on an SDS-PAGE gel and the proteins visualized by Coomassie 
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stain. To examine ubiquitination of RING1B by UBE3A, radiolabeled RING1B-I53S was 
incubated with baculovirus-expressed E1, E2 (UbcH7), and UBE3A at 30°C for 90 min in the 
presence or absence of ATP and/or E6. The reaction mixture was electrophoresed on an SDS-
PAGE gel and visualized by fluorography.  
Lentiviral production and transduction of NPCs 
HA-tagged E6 was cloned downstream of the ubiquitin C promoter of the FUGW plasmid100 
(Addgene #14883) connected to GFP by T2a (Supplemental Figure S8A). pcDNA3 plasmid 
containing HA-tagged E6101 and FUGW were used as templates for molecular cloning, which 
was performed by the iPSC/hESC Genome Targeting division of the UConn-Wesleyan Stem 
Cell Core. The plasmid was verified by transfecting 293FT cells with E6-containing or normal 
FUGW using Lipofectamine 3000 (Life Technologies). 48 hours after transfection, GFP 
expression was confirmed by live cell imaging, and GFP and HA tag expression confirmed by 
Western blot (Supplemental Figure S8B). Lentiviral particles were made by transfecting 293FT 
cells with 2nd generation packaging systems using Lipofectamine 3000. Virus was concentrated 
using the Lenti-X Concentrator Kit (Clontech) and viral titer calculated using the qPCR Lentivirus 
Titration Kit (abm). 48 hours after thawing, 5.5-week NPCs were transduced with FUGW-E6 or 
FUGW virus for 24 hours by adding concentrated lentivirus directly to NDM. NPCs were plated 
for terminal differentiation at approximately 6.5 weeks onto glass coverslips. Coverslips were 
fixed for ICC at 11-11.5 weeks or subject to electrophysiological recordings at 12 weeks. 
Quantitative RT-PCR 
cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific) according to manufacturer’s instructions. Quantitative RT-PCR was performed 
using Taqman Gene Expression Assays and Mastermix (Thermo Fisher Scientific) on the Step 
One Plus (Thermo Fisher Scientific). Reactions were performed in technical duplicates, with 
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GAPDH Endogenous Control Taqman Assay used as the housekeeping gene for normalization. 
Gene expression was quantified using the ΔΔCt method. 
Immunocytochemistry 
Immunocytochemistry was performed on stem cells or neurons as previously described.79 
Briefly, cells were fixed using room temperature 4% paraformaldehyde then permeabilized using 
0.5% PBS-Triton X 100 (PBS-T) for 10 min at room temperature. Cells were blocked in 0.1% 
PBS-T containing 2% bovine serum albumin and 5% normal goat serum. Cells were incubated 
in primary antibody in blocking buffer overnight at 4°C then washed with 0.1% PBS-T. Cells 
were then incubated in secondary antibody in blocking buffer for 1 hour at room temperature 
then washed with 0.1% PBS-T. Cells were mounted with either Vectashield Hard Set with DAPI 
(Vector Laboratories) or ProLong Gold Anti-Fade Hard Set with DAPI (ThermoFisher Scientific) 
and allowed to set overnight at room temperature before imaging. Slides were imaged on a 
Zeiss Axiovision microscope at 20x, 40x, or 63x using Axiovision Software (Zeiss). For 
pluripotency staining of iPSCs/hESCs, the following antibodies were used: rabbit anti-OCT4 
(1:200; Stemgent 09-0023), mouse anti-SSEA4 (1:20; ThermoFisher MA1-021), mouse anti-
TRA-1-60 (1:200 Santa Cruz sc-21705), anti-mouse Alexa Fluor 488 (1:500). For the E6 
experiments, the following antibodies were used: chicken anti-MAP2 (1:10,000, abcam), rabbit 
anti-HA (1:1200, Cell Signaling), mouse anti-GFP (1:750, Invitrogen), anti-chicken Alexa Fluor 
647 (1:250, abcam), anti-rabbit Alexa Fluor 594 (1:400, Invitrogen), anti-mouse Alexa Fluor 488 
(1:400, Invitrogen). 
Western Blots 
Cells were lysed using PathScan Lysis Buffer (Cell Signaling Technology) supplemented with 1 
mM phenylmethane sulfonyl fluoride (PMSF; Gibco) and Protease Inhibitor Cocktail III (1:200; 
Calbiochem). Total protein concentration was quantified using the BCA Protein Assay Kit 
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(ThermoFisher). Total cell lysate was separated by SDS-PAGE using 4-20% TGX Stain-Free 
mini gels (BioRad). Protein was transferred to PVDF membrane using the TransBlot Turbo 
system (BioRad). Membranes were blocked in 5% BSA in TBS-T (Tris-buffered saline plus 0.1% 
Tween-20) for 1 hour at room temperature then incubated in blocking buffer containing primary 
antibodies overnight at 4°C. Membranes were washed with TBS-T at room temperature, 
incubated in blocking buffer containing HRP-conjugated secondary antibodies for 1 hour at 
room temperature, then washed again in TBS-T. All washes were done three times for 10-12 
minutes each at room temperature. Membranes were imaged using the Clarity Western ECL 
substrate (BioRad) on the ChemiDoc Touch Imaging System (BioRad). The following primary 
antibodies were used: rabbit anti-UBE3A (Bethyl Laboratories Inc., 1:3000), mouse anti-GAPDH 
(Millipore, 1:10,000), mouse anti-GFP (Invitrogen, 1:3000), rabbit anti-HA (Cell Signaling 
Technology, 1:1000). HRP-conjugated secondary antibodies (Cell Signaling Technology) were 
used at 1:4000 (anti-rabbit). 
Statistical Analysis & Graphing 
Statistical analysis of all qRT-PCR and electrophysiology data was performed on SPSS 
Statistics 25 software (IBM). Graphs were generated using Graphpad Prism or R studio. 
Live cell imaging 
To confirm expression of GFP in live neurons transfected with either E6-FUGW or FUGW virus, 
coverslips were inverted and placed in a RX-26G imaging chamber (Harvard Apparatus) 
containing Live Cell Imaging Solution (ThermoFisher). Cells were imaged on the Zeiss 780 
confocal microscope with 63x oil immersion objective (numerical aperture of 1.4, 3x zoom). 
Images were acquired using ZEN microscope software (Zeiss). 
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Results 
Generation of isogenic AS and control stem cell lines  
We first sought to generate two isogenic AS and control stem cell pairs. Using isogenic cell 
pairs would establish an important resource for AS research in which molecular and phenotypic 
differences caused by normal human variation could be minimized. The first isogenic pair was 
established by correcting AS Pt Mut iPSCs to a normal genotype using CRISPR/Cas9. These 
iPSCs were derived from an AS patient with an inherited UBE3A missense mutation (Figure 
1A-B). The missense mutation caused no reduction in the protein levels of UBE3A (Figure 1C). 
This AS-causing mutation was located upstream of a PAM site for S. pyogenes Cas9, enabling 
us to design a CRISPR that preferentially targeted the maternal allele (Figure 1D). To correct 
this mutation, a single-stranded oligonucleotide (ssODN) containing the wildtype UBE3A 
sequence, and a silent mutation to limit CRISPR cutting of the corrected allele and to facilitate 
clone screening, was used as the template for homology directed repair (Figure 1D). Using this 
method, we were able to generate a control iPSC line isogenic to the AS iPSCs (Corrected; 
Figure 1E-G). 
 The second isogenic pair was established by using CRISPR/Cas9 to delete the maternal 
copy of UBE3A in H9 hESCs. For this approach a pair of CRISPRs flanking the UBE3A gene 
was used to induce double-stranded breaks at the 5’ and 3’ ends of the gene (Figure 2A). Due 
to error-prone non-homologous end-joining (NHEJ), deletions, duplications, or inversions can 
occur, which can then be screened for by conventional PCR (Figure 2A,B), as previously 
described.88 We identified a single clone in which only one copy of UBE3A had been deleted 
and the other allele was devoid of any insertions, deletions, or inversions (Figure 2B, 
Supplemental Figure S2). To determine which copy of UBE3A had been deleted, we identified 
a heterozygous SNP (rs104193347) in an intron of UBE3A in H9 hESCs and determined its 
allelic identity using strand-specific reverse transcription polymerase chain reaction (RT-PCR) 
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followed by sequencing in neurons (Figure 2C). UBE3A-ATS is produced exclusively by the 
paternal allele in neurons and spans the introns of UBE3A, which enabled us to infer the 
parental origin of each SNP allele. We then used Sanger sequencing to determine the identity of 
the SNP in the genomic DNA of the remaining intact allele. We were able to determine that the 
maternal allele of UBE3A had been deleted (Figure 2C). We further confirmed that the other 
allele had not been disrupted in this clone by assaying UBE3A expression by qRT-PCR and 
Western blot (Figure 2D-E), which showed a reduction, but not loss, of UBE3A levels. For both 
isogenic pairs, it was confirmed that genome editing did not affect expression of pluripotency 
markers or cause any large-scale genomic rearrangements (Supplemental Figures S1&S2). 
Isogenic AS stem cell-derived neurons display AS electrical phenotypes 
 Previously we showed that AS iPSC-derived neurons display impaired neuronal 
maturation in vitro, including a more depolarized resting membrane potential (RMP), less 
mature action potential (AP) firing patterns, and less frequent spontaneous excitatory synaptic 
activity.76 To confirm that our AS neurons also exhibited AS phenotypes when compared to their 
isogenic controls, we performed whole cell patch clamp recordings. Both AS Pt Mut iPSC-
derived and ΔUBE3Am-/p+ hESC-derived neurons displayed impaired electrical maturity when 
compared to their respective isogenic controls (Figure 3). This also confirmed that the genome 
editing of the stem cells achieved its desired effects: the correction of the AS mutation in the 
iPSCs produced electrically normal neurons (Figure 3A-C), while deletion of UBE3A in normal 
hESCs produced neurons that recapitulated most AS phenotypes (Figure 3D-F). 
Establishing a molecular AS phenotype using the transcriptome 
 Currently there are multiple approaches being explored as potential AS therapies, many 
of which are based on DNA sequences unique to humans. Testing these therapies in mouse 
requires either use of a different sequence, which does not actually test the putative human 
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therapeutic, or the costly and at times challenging development of humanized murine models. 
Stem cell-derived neurons allow us to test these potential therapies on human neurons in dish, 
a step that is especially necessary for nucleic acid-based therapeutic approaches. Just as 
important as being able to test these drugs, however, is the ability to begin to assess their 
efficacy. We wanted to see if we could use the transcriptome of human neurons to establish a 
quantitative molecular phenotype for AS. Specifically, we sought to identify a list of genes that 
are consistently differentially expressed between AS and neurotypical stem cell-derived 
neurons. Our goal in this approach was not identify putative UBE3A targets that might be 
affected in AS but to get a definitive set of genes that reflect our ability to restore function to AS 
neurons following drug treatment. 
 mRNAseq was performed on 12-week neurons differentiated from the AS Pt Mut, 
Corrected, H9, and ΔUBE3Am-/p+ stem cell lines. Three separate analyses were conducted to 
produce a conservative list of genes consistently differentially expressed between AS and 
neurotypical neurons: AS Pt Mut vs Corrected, H9 vs ΔUBE3Am-/p+, and AS+ΔUBE3Am-/p+ vs 
Corrected+H9. For each of the three comparisons, surrogate variable analysis was performed 
prior to intersection with the other pairs to remove the variation not conferred by genotype (see 
Supplemental Figure S4). The final list of differentially expressed (DE) genes consisted of 
genes that were significantly differentially expressed in all three analyses (n = 855 genes, padj < 
0.01; Figure 4A-B). As we suspected, this gene list did not contain any known ubiquitylation 
substrates for the UBE3A protein and most likely reflects genes whose change in expression 
were secondary or tertiary to loss of UBE3A function. Indeed, when we examined gene 
expression changes in normal hESC-derived neurons which had undergone an acute antisense 
oligonucleotide-mediated UBE3A knockdown, we saw significant changes in 15 genes, none of 
which, aside from UBE3A itself, had dramatic changes in gene expression (Supplemental 
Figure S6). This suggests that there are few, if any, direct transcriptional targets of UBE3A in 
our human neuron cultures. Furthermore, of the small handful of significant genes, none 
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appeared on our list of AS DE genes. Finally, gene ontology (GO) analysis of our set of AS DE 
genes revealed differences in processes such as extracellular matrix, cell adhesion, and 
synaptic signaling (Figure 4C). 
Rescue of AS differentially expressed genes by restoring UBE3A function 
 To determine whether genes identified by mRNAseq could be used as a readout for 
treated AS neurons, we examined the expression of 11 genes from our list by qRT-PCR. We 
wanted to assess whether we could see restoration of the transcriptome phenotype after 
restoring function to the mutant UBE3A protein in AS point mutation neural progenitor cells 
(NPCs). This missense mutation in the AS Pt Mut iPSCs changes an amino acid in the HECT 
domain of the UBE3A protein, which confers ubiquitin ligase activity. Because this mutation did 
not cause a loss of UBE3A protein (Figure1C, G), we hypothesized that it might instead cause 
a loss of protein function. As seen in Figure 5A, the ability of the mutant version of UBE3A to 
ubiquitinate itself or RING1B was severely diminished in an in vitro ubiquitination assay. 
Interestingly, in the presence of the E6 oncoprotein, ubiquitin ligase activity of the mutant 
version of UBE3A could be rescued. In the context of cervical cancer, the E6 oncoprotein, 
produced by the human papilloma virus (HPV), acts as an allosteric activator of UBE3A, 
allowing it to ubiquitinate substrates that it normally would not target, such as p53.41 
 We reasoned that E6 might also be able to activate this mutant version of UBE3A in our 
cultured AS patient-derived cells. Five-week AS Pt Mut neural progenitor cells were treated with 
virus expressing HA-tagged E6 and GFP or virus expressing GFP alone (Figure 5B; 
Supplemental Figure S7C). Whole-cell patch clamp recordings of GFP+ cells revealed that 
treatment with E6 rescued resting membrane potential in AS Pt Mut neurons while having no 
effect on RMP in the isogenic control E6-treated neurons (Figure 5C). Conversely, E6 treatment 
did not significantly affect AP firing in AS Pt Mut neurons, but appeared to negatively affect AP 
firing in Corrected neurons (Figure 5C), indicating that E6 expression may be detrimental to 
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some aspects of normal neuronal function. We next assayed the expression of 11 genes from 
the DE gene list that had an absolute log2 fold change (log2fc) of greater than one. All 11 genes 
assayed recapitulated the gene expression changes seen in the mRNAseq data (Figure 5D 
(black)) when comparing differences in expression between the AS Pt Mut/GFP to the 
Corrected/GFP neurons. Importantly, treatment of AS neurons with E6 caused significant 
changes in gene expression in seven of the genes assayed (Figure 5D (red)). Together, these 
results validate our mRNAseq data and demonstrate the utility of using the transcriptome as a 
phenotype for AS neurons following treatments. 
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Discussion 
AS is a rare neurodevelopmental disorder for which there is currently no cure, that is caused by 
loss of the maternal copy of the UBE3A gene. Previously, we had established AS iPSC lines, 
which were shown to undergo normal imprinting of UBE3A upon differentiation into neurons.78 
We also showed that AS iPSC-derived neurons display impaired neuronal maturation compared 
to control iPSC-derived neurons, and that these electrophysiological phenotypes were a result 
of the lack of UBE3A in these cells.76 Here, we have used isogenic AS and neurotypical neurons 
to establish a robust quantitative molecular phenotype for AS neurons by comparing the 
transcriptomes of isogenic AS and neurotypical neurons We have identified a list of genes that 
can be assayed in human neuronal cultures following drug treatments to determine the ability of 
the drug to rescue human AS stem cell derived neurons. 
 We chose to employ a more conservative approach to our mRNAseq analyses in order 
to establish a robust and replicable phenotype for AS neurons. First, we established two 
isogenic pairs of AS and control stem cells, one by correcting AS in iPSCs and one by causing 
AS in hESCs. By examining more than one pair of isogenic cells, which were derived from 
individuals with two distinct genetic backgrounds, we can more confidently say that the gene list 
identified reflects gene expression changes seen in AS neurons. Second, we performed a third 
analysis in which all 12 AS samples were compared to the 12 control samples, and looked for 
genes in common between this analysis and the other two analyses. Finally, we employed 
surrogate variable analysis98 in an attempt to account for other extraneous factors102 that could 
have caused differences in gene expression, which has been previously shown to improve the 
accuracy of fold-change estimates103. The result of this more cautious approach was still a 
relatively large list of 855 genes that were differentially expressed in AS versus neurotypical 
neurons. We propose that this list of genes, as a whole or in part, can be assayed following drug 
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treatments of AS neurons by any desired means, such as qRT-PCR, custom qRT-PCR array, 
targeted sequencing, or whole transcriptome profiling. 
 To validate the use of the transcriptome as a phenotype, we assayed a small portion of 
this gene list by qRT-PCR after restoring ubiquitin ligase function to UBE3A in the AS Pt Mut 
NPCs. AS Pt Mut and Corrected NPCs were treated with virus expressing E6 oncoprotein, 
which we showed can rescue the activity of the mutant version of UBE3A seen in this AS patient 
in an in vitro ubiquitination assay. We showed that treatment of AS NPCs with E6, in addition to 
rescuing resting membrane potential deficits in AS neurons, was able to partially rescue the 
expression of the DE genes assayed. While treatment with E6 itself is not an ideal potential AS 
therapy due to potential off-target gene expression changes independent of UBE3A function, 
these findings confirm the robustness and utility of using differentially expressed AS genes as a 
readout for in vitro drug treatments. This phenotype will be especially useful for therapies that 
specifically modulate UBE3A’s expression or function, such as through unsilencing of paternal 
UBE3A or through introduction of exogenous UBE3A expression. 
 The results of these experiments were not intended to identify putative pathways that are 
misregulated in AS, nor were they intended to identify putative transcriptional or ubiquitylation 
targets of UBE3A in neurons. The gene expression changes seen in the AS neurons instead 
reflect secondary or tertiary changes following loss of UBE3A and, presumably, overabundance 
of UBE3A’s as-yet-unknown neuronal targets. Consistent with this notion, gene expression 
changes seen in neurons with acute UBE3A knockdown by ASO, which would more accurately 
reflect primary gene expression changes immediately following UBE3A loss, do not reflect the 
changes seen in the AS neuron transcriptome, and overall very few genes are changed. That 
being said, some of the differentially expressed genes do recapitulate physiological AS in vitro 
phenotypes and may suggest other important AS pathologies. For example, we see decreased 
expression of mature neuron markers such as TBR1, NEUROD2, and BCL11B (CTIP2) in AS 
neurons compared to neurotypical controls, and GO analysis revealed decreases in genes 
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implicated in synaptic transmission. These results are reminiscent of the decreased electrical 
maturity in AS neurons that we have shown previously76 and in this study. Additionally, we see 
an upregulation of genes involved in the extracellular matrix and in cell adhesion in AS neurons 
compared to controls, which may indicate a novel pathology for cultured AS neurons. 
Interestingly, we showed that we could reactivate the mutant form of UBE3A by introduction of 
the E6 oncoprotein, a known allosteric activator of UBE3A,41 and rescue both electrical and 
transcriptome phenotypes. While E6 itself is not a viable therapeutic target for AS, these data 
serve as an important proof of principle that for some AS-causing mutations, we can rescue or 
increase UBE3A’s ubiquitin ligase activity through its activation. It is possible that the effects of 
E6 on UBE3A could be mimicked by small molecules, which could be a therapeutic approach 
for a subset of AS patients. 
 In addition to our transcriptome phenotype, we have also demonstrated that the AS Pt 
Mut and ΔUBE3Am-/p+ stem cell-derived neurons display the same electrical phenotypes 
demonstrated previously. This is important because it demonstrates that AS neurons display 
these electrical phenotypes regardless of which protocol is used to differentiate them 
(monolayer, shown here, versus embryoid body, used previously). Additionally, both the 
electrophysiological and transcriptome phenotypes are seen in neurons derived from the AS Pt 
Mut iPSCs, which actually have normal levels of UBE3A protein, but produce a version of the 
protein that is virtually ligase-dead. This implies that loss of UBE3A’s ubiquitin ligase activity 
alone is sufficient to produce AS, both in vitro and in vivo (as demonstrated by the two AS 
patients with this mutation). Although we did not see significant changes in the frequency of 
spontaneous excitatory synaptic activity in the ΔUBE3Am-/p+ neurons when compared to their 
isogenic control, we believe that this may be due to the decreased number of cells used for 
these recordings as compared to the AS Pt Mut and Corrected neurons, and also compared to 
our previous work. Supportive of this notion is the fact that the difference between the AS Pt Mut 
and Corrected neurons (.27 Hz) is of similar magnitude to the difference between the H9 and 
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ΔUBE3Am-/p+ neurons (.45 Hz). It should also be noted, however, that these neurons in general 
had dramatically more frequent spontaneous excitatory activity than the AS and corrected 
neurons and also in our previous work, so it is possible that AS neurons with a higher frequency 
of spontaneous synaptic events do not display these deficits. 
 This study is not without its limitations. AS is caused by large deletions of the 15q11-q13 
region in the majority of patients.22 These deletions encompass not only UBE3A, but multiple 
other non-imprinted genes, such as GABRB3, GABRA5, and HERC2. It was our goal to identify 
gene expression changes in AS neurons that arise specifically due to loss of UBE3A, which we 
can ideally apply to neurons from AS patients with any type of genetic etiology. It is possible, 
however, that reduced expression of the non-imprinted genes in this chromosomal region could 
affect expression of some of the genes from our list in cells derived from these patients. Another 
caveat is that our conservative criteria for establishing our list of AS DE genes may have 
excluded other AS DE genes, which could have impacted the results of our GO analysis. Since 
our goal here was not to identify or study pathways altered in AS, we were not concerned by 
this. However, it is something that should be kept in mind when considering the GO results 
presented here. 
 In summary, we have demonstrated that AS neurons, when compared to isogenic 
controls, have changes in the transcriptome that are consistent across isogenic pairs. We have 
identified a list of genes that can serve as a robust molecular phenotype for cultured human 
stem cell-derived AS neurons, which we can now assay in rescue experiments. We propose to 
use this phenotype as high-throughput method for assessing the efficacy of potential AS 
therapeutics in cultured human neurons. This is a necessary step, especially for gene therapy-
based approaches, before these therapies can proceed to clinical trials. By more thoroughly 
vetting potential therapies before trials, we can improve the likelihood of identifying a therapy for 
AS that is both safe and effective. 
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Figure 1. Generation of isogenic control iPSC line by correcting AS point mutation 
A Pedigree showing family with AS point mutation. Arrow indicates proband. Star indicates AS 
point mutation. B Sanger sequencing of iPSC gDNA showing point mutation (arrow) C Western 
blot showing normal levels of UBE3A protein in AS Pt Mut iPSCs compared to AS large deletion 
(AS Del 1-0) and normal (NML1-0) iPSCs D Top: Location of gRNA binding site (red), PAM 
(blue), and CRISPR cut site (T) Middle: gRNA sequence; Bottom: ssODN sequence * = location 
of mutation/correction; C = silent mutation to create FokI site E Sanger sequencing of iPSC 
gDNA showing correction of point mutation following genome editing F qRT-PCR showing 
UBE3A levels in AS and corrected iPSCs G Western blot showing UBE3A levels in AS Pt Mut 
and Corrected iPSCs 
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Figure 2. Generation of isogenic AS hESCs by deleting maternal UBE3A 
A Top: Schematic illustrating CRISPR gRNA and primer locations, as well as the location of 
rs1041933 (light blue arrow). Red box indicates approximate location of gRNA binding/CRISPR 
cutting. Bottom: Location of gRNA (underlined) and PAM site (blue), as well as the STOP codon 
(red) and translational start site (green). B PCR of gDNA indicating heterozygous deletion of 
one copy of UBE3A. Numbers correspond to primers in part A above. C Top: Sanger 
sequencing of cDNA from the UBE3A-ATS transcript. Bottom: Sanger sequencing of gDNA from 
the intact allele of the deletion clone showing SNP rs1041933 D qRT-PCR showing UBE3A 
levels in H9 and ΔUBE3Am-/p+ hESCs E Western blot showing UBE3A levels in H9 and 
ΔUBE3Am-/p+ hESCs 
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Figure 3. Isogenic AS neurons display AS electrical phenotypes 
A Resting membrane potential in AS Pt Mut and Corrected iPSC-derived neurons B Left: action 
potential firing characterization of AS Pt Mut and Corrected neurons; right: sample AP traces  
C Excitatory spontaneous synaptic activity frequency (left) and amplitude (right) in AS Pt Mut 
and Corrected neurons. n = 90-120 neurons on 6-8 coverslips per cell line D Resting membrane 
potential in ΔUBE3Am-/p+ and H9 hESC-derived neurons E Left: AP firing characterization of 
ΔUBE3Am-/p+ and H9 neurons; right: sample AP traces F Excitatory spontaneous synaptic 
activity frequency (left) and amplitude (right) in ΔUBE3Am-/p+ and H9 neurons. n = 53-54 neurons 
on 4 coverslips per cell line.  * p < 0.05; *** p < 0.005; RMP, frequency, amplitude: student’s t-
test; AP firing: Χ2 test 
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Figure 4. Establishing a transcriptome phenotype for AS neurons 
A Heatmap showing expression of 855 genes differentially expressed in AS (padj < 0.01) B 
Weighted Venn diagrams comparing the three mRNAseq analyses showing common genes 
decreased (top) or increased (bottom) in AS neurons C Dot plots showing the top 5 significant 
functional annotation clusters and the top 5 GO terms in each cluster for DOWN (left) and UP 
(right) AS DE genes. Dot size indicates number of genes belonging to that term, color indicates 
enrichment score. Benjamini test p < 0.05 
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Figure 5. Rescue of ubiquitin ligase activity of mutant UBE3A partially restores AS 
phenotypes 
A In vitro ubiquitination assay showing levels of ubiquitinated (**) and non-ubiquitinated (*) 
UBE3A (left) or RING1B (right) in the presence of wild-type (WT) or mutant (AS mut) UBE3A 
protein B Immunocytochemistry showing expression of GFP (green) in virus-treated MAP2+ 
(blue) neurons and expression of HA-tagged E6 (red) in E6-treated neurons C/D Effect of E6 
treatment on resting membrane potential (RMP) and action potential firing (AP firing) AS 
phenotypes. n = 23-34 neurons on 6-8 coverslips per condition. E Scatterplot showing 
correlation between expression of DE genes from mRNAseq data (x-axis) and qRT-PCR of E6 
(red) or GFP (black) treated neurons (y-axis). Scale bar = 20 μm; * p < 0.05 ** p < 0.01 *** p < 
0.005 (C, students t-test; D, Χ2 test; E, linear regression) 
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Figure S1. Characterization of AS Pt Mut and Corrected iPSCs 
Top: expression of pluripotency markers in AS Pt Mut (left) and Corrected (right) iPSCs 
Middle: qRT-PCR showing that AS Pt Mut and Corrected iPSCs have similar levels of 
expression of pluripotency genes 
Bottom: AS Pt Mut (left) and Corrected (right) iPSCs have a normal karyotype 
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Figure S2. Characterization of ΔUBE3Am-/p+ hESCs 
Top: CRISPR editing of H9 line did not affect expression of pluripotency markers 
Middle left: qRT-PCR showing that ΔUBE3Am-/p+ hESCs express similar levels of pluripotency 
genes compared to its parent line, H9 
Middle right: ΔUBE3Am-/p+ hESCS have a normal karyotype after genome editing 
Bottom: Sanger sequencing shows no indels present at the CRISPR cut sites at either the 5’ 
(left) or 3’ (right) sites. Scissors indicates the specific CRISPR cut site. Black line indicates 
sgRNA binding site. Red line indicates the PAM site. The UBE3A STOP codon is highlighted in 
blue (right). 
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Figure S3. Additional information about the hPSC-derived neurons 
A MA plots showing DE genes (red) in AS Pt Mut vs Corrected (left) and H9 vs ΔUBE3Am-/p+ 
(right) neurons. Neuronal and neural development genes are highlighted in blue. B Action 
potential properties in AS Pt Mut vs Corrected (top) and H9 vs ΔUBE3Am-/p+ (bottom) neurons. * 
p < 0.05, *** p < 0.005 (student’s t-test) 
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Figure S4. Principal component analysis plots before and after surrogate variable 
analysis 
Left: PCA before SVA, right: PCA after SVA. A AS Pt Mut vs Corrected B H9 vs ΔUBE3Am-/p+ 
C Combined analysis 
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Figure S5. Scatterplot matrix 
Scatterplot matrix showing degree of correlation between all 24 samples used in mRNAseq 
analysis to establish transcriptome phenotype. R indicates Pearson correlation. 
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Figure S6. DE genes after acute UBE3A knockdown via ASO treatment 
MA plot showing DE genes (red) in ASO- vs scramble-treated H9 neurons. UBE3A is 
highlighted in blue. 
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Figure S7. Generation and validation of E6-GFP system 
A Map of FUGW vector after insertion of HA/E6-T2A-GFP B Western blot showing expression 
of GFP and HA tag in HEK293T cells following transfection with E6-FUGW or FUGW vector. C 
Live cell image of FUGW transfected neurons showing transfection of only a proportion of 
neurons. Scale bar = 10 μm 
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Table S1 PCR Primers 
Name Sequence 
Point Mut F TTCATCAGTCCTTAATAAAATACAAAA 
Point Mut R TTTTCCCCATTAGCTTCCT 
Point Mut Seq AGGTATGTTCACATACGATG 
Iso1 F GCTTATAATGGCTTGTCTGTTGG 
Iso1 R CTGCTACCAGGGAAGCAAAA 
Iso1 Seq TTCTTTCATGTTGACATCTTTAATTTT 
UBE3A 3’ R TGGGACACTATCACCACCAA 
UBE3A_del_F1 AGTCCAACCCTTAAAATAAATGTG 
UBE3A_del_R1 CCCACATGTCCCCAATAAAG 
UBE3A_intron12_F1 GGCAACTTGGTAGTTACACAACA 
UBE3A_intron12_F2 CCCATGACTTACAGTTTTCCTG 
EndogNeo F TGAAACACTTTGGAAATGTAGCC 
EndogNeo R GCACTTGAGAAAACAATGTCCA 
SNP -933 F TTAAGCAGTTGCCCTCCTTG 
SNP -933 R AAAATTAAGCAGCCTCCGAGT 
SNP -933 Seq TGACTGAATTTGTCCGTATTTGA 
SDM 1F ATGCCATTGTTGCTGCTTC 
SDM 1R new CAAGTGTATGCTACTTAGATGTTTTAACAAAACCAAAT 
TAGGTAGAAGAAGACTTTGACT 
SDM 1R ctrl CAGAAGAAGATGGATTAAACCAAAA 
SDM 2F new CCATCTTCTTCTGAAACTGAGGGTCAGTTTACTCTGAT 
TGGCATAGTACTGGGTCTGGCT 
SDM 2R CCTGTAGACAACCATGGGAAA 
SDM seq F ATGCAGACCAGATTCGGAGA 
SDM seq R TCATCTTCCACATTCCCTTCA 
 
Table S2 Taqman assays used for mRNAseq validation 
Gene Assay 
NEUROD2 Hs00272055_s1 
COL6A6 Hs01029204_m1 
GRM3 Hs00932301_m1 
TBX18 Hs01385457_m1 
GJA5 Hs00979198_m1 
WISP1 Hs04234730_m1 
BCL11B Hs01102259_m1 
MGP Hs00969490_m1 
TBR1 Hs00232429_m1 
EDNRA Hs03988672_m1 
C7 Hs00175109_m1 
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Table S3 mRNAseq sample information 
Sample Trimmomatic STAR    
 
% passing - 
paired 
Total 
mapped 
Uniquely 
mapped 
Multi-
mapped Unmapped 
AS1 95.79% 78.60% 74.82% 3.78% 21.40% 
AS2 93.93% 94.87% 90.55% 4.32% 5.13% 
AS3 93.44% 88.38% 84.40% 3.99% 11.62% 
AS4 99.87% 94.40% 90.37% 4.03% 5.60% 
AS5 99.29% 93.56% 89.51% 4.05% 6.44% 
AS6 98.58% 88.23% 84.24% 3.98% 11.77% 
CORR1 99.89% 93.88% 89.71% 4.17% 6.12% 
CORR2 99.41% 89.03% 84.79% 4.25% 10.97% 
CORR3 98.51% 90.58% 86.13% 4.44% 9.42% 
CORR4 99.85% 96.57% 92.36% 4.21% 3.43% 
CORR5 99.92% 92.57% 88.44% 4.13% 7.43% 
CORR6 97.98% 88.50% 84.39% 4.11% 11.50% 
H9 1 99.82% 95.89% 92.17% 3.72% 4.11% 
H9 2 99.90% 89.27% 85.97% 3.30% 10.73% 
H9 3 99.88% 94.86% 91.15% 3.71% 5.14% 
H9 4 99.82% 93.46% 89.89% 3.57% 6.54% 
H9 5 99.86% 92.67% 89.05% 3.62% 7.33% 
H9 6 99.83% 94.58% 90.02% 4.55% 5.42% 
UBE3Adel 1 99.92% 93.86% 89.89% 3.97% 6.14% 
UBE3Adel 2 99.95% 93.66% 89.27% 4.39% 6.34% 
UBE3Adel 3 99.94% 89.08% 85.16% 3.93% 10.92% 
UBE3Adel 4 99.96% 94.23% 86.09% 8.15% 5.77% 
UBE3Adel 5 99.96% 94.91% 90.62% 4.29% 5.09% 
UBE3Adel 6 99.92% 94.29% 89.80% 4.49% 5.71% 
ASO1 99.88% 95.52% 91.62% 3.91% 4.48% 
ASO2 99.69% 96.16% 91.76% 4.40% 3.84% 
ASO3 99.91% 97.22% 92.65% 4.56% 2.78% 
ASO4 99.58% 95.35% 91.23% 4.12% 4.65% 
ASO5 99.44% 94.29% 89.40% 4.89% 5.71% 
ASO6 99.31% 97.03% 92.14% 4.90% 2.97% 
Scram1 99.80% 90.06% 86.08% 3.98% 9.94% 
Scram2 99.89% 96.21% 91.68% 4.53% 3.79% 
Scram3 99.79% 95.72% 91.61% 4.12% 4.28% 
Scram4 99.55% 97.27% 92.98% 4.29% 2.73% 
Scram5 99.80% 95.54% 91.47% 4.09% 4.46% 
Scram6 99.51% 96.69% 92.38% 4.30% 3.31% 
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Table S4 mRNAseq analysis software versions 
Software/Program Version 
FastQC v0.11.5 
Trimmomatic104 v0.36 
Python v2.7.8 
MultiQC105 v1.1 
STAR106 v2.5.3a 
RStudio v1.1.423 
R v3.5.0 
DEseq2107 v1.20.0 
org.Hs.eg.db v3.6.0 
AnnotationDbi v1.42.1 
ggplot2 v3.0.0 
pheatmap v1.0.10 
RColorBrewer v1.1-2 
sva98 v3.28.0 
vidger v1.0.0 
rgl v0.99.16 
rmarkdown v1.10 
dendextend v1.8.0 
gplots v3.0.1 
Vennerable v3.1.0.9000 
RBGL v1.56.0 
graph v1.58.0 
RDAVIDWebService108 v1.18.0 
rJava v0.9-10 
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Abstract 
 Loss of expression of UBE3A, a gene regulated by genomic imprinting, causes 
Angelman Syndrome, a rare neurodevelopmental disorder. The UBE3A encodes an E3 ubiquitin 
ligase with three known protein isoforms in humans. Studies of the mouse isoforms suggest that 
the human isoforms may have differences in localization and neuronal function, and recently 
published AS case studies also indicate that the isoforms may play a role in AS. Here we have 
used CRISPR/Cas9 to generate human embryonic stem cells that lack the individual protein 
isoforms. We demonstrate that protein isoform 1 accounts for the majority of UBE3A protein in 
hESCs and neurons. We also show that all three isoforms predominantly localize to the 
cytoplasm in both cell types. Finally, we show that neurons lacking isoform 1 only recapitulate 
some of the phenotypes displayed by cultured AS neurons.  
Introduction 
 Angelman Syndrome (AS) is a rare neurodevelopmental disorder that affects 1 in 15,000 
individuals, characterized by severe seizures, intellectual disability, absent speech, ataxia, and 
happy affect.20 The causative gene for AS, UBE3A, is regulated by tissue-specific genomic 
imprinting – it is expressed exclusively from the maternal allele in neurons and is expressed 
biallelically in other cell types.11,21 The UBE3A gene encodes an E3 ubiquitin ligase that adds 
polyubiquitin chains to substrates, targeting them for degradation by the 26S proteasome.25 In 
humans, there are three known UBE3A protein isoforms,46 all of which are full length and 
therefore are presumably capable of functioning as an E3 ligase. Human isoforms 2 and 3 only 
differ from human isoform 1 by 23 and 20 amino acids at their N terminus, respectively.48 While 
there has been little published research examining the human protein isoforms, studies 
performed in mouse indicate that the isoforms likely have differences in their localization and 
function.49,50 It is also currently unknown whether the different isoforms play a role in AS. This is 
knowledge is important as some therapeutic avenues currently being explored for AS involve 
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delivery and expression of exogenous UBE3A transgenes using vector-based therapies.71 For 
these approaches, knowledge of which protein isoforms need to be replaced in AS is essential. 
Recently, Sadhwani and colleagues published three cases of AS caused by missense 
mutations at the isoform 1 translational start site.77 Interestingly, these patients present with 
milder phenotypes than AS patients with 15q11-q13 deletions or other UBE3A loss of function 
mutations, including normal gait and use of syntactic speech. This data, coupled with the fact 
that the human and mouse isoforms are not entirely conserved, illustrates the need to study the 
human UBE3A protein isoforms specifically, as they may play a role in both normal neuronal 
function and in disease. Here, we have used human embryonic stem cells (hESCs) and their 
neuronal derivatives to examine the abundance and localization of the three human isoforms. 
We have also examined whether neurons lacking individual protein isoforms recapitulate any 
AS phenotypes previously seen in induced pluripotent stem cell (iPSC)- and hESC-derived 
neurons. We show that in both hESCs and hESC-derived neurons, all three UBE3A protein 
isoforms are predominantly localized to the cytoplasm, with low levels of expression in other 
cellular compartments. We also show that protein isoform 1 is the predominant protein isoform 
in human cells. Finally, we show that neurons lacking isoform 1 show some, but not all, of the 
phenotypes displayed by AS stem cell-derived neurons, while loss of isoform 2 or 3 does not 
produce any phenotypic changes. These results not only provide useful insight into the human 
UBE3A isoforms, but also provide information important for the development of potential AS 
therapies. 
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Methods 
hESC culture and neural differentiation 
hESCs were cultured on irradiated mouse embryonic fibroblasts and fed daily with hESC media 
(DMEM/F12 containing knockout serum replacement, L-glutamine + β-mercaptoethanol, non-
essential amino acids, and basic fibroblast growth factor). hESCs were cultured in at 37°C in a 
humid incubator at 5% CO2. Cells were manually passaged every 5-7 days. 
hESCs were differentiated into neurons using a modified version of the monolayer protocol. 
Neural induction was begun 2 days after passaging by cultured cells in N2B27 medium 
(Neurobasal medium, 1% N2, 2% B27, 2 mM L-glutamine, 0.5% penicillin/streptomycin, 1% 
insulin-transferrin-selenium). N2B27 medium was supplemented with fresh Noggin (500 ng/mL) 
for the first 10 days of differentiation. Neural rosettes were manually passaged onto poly-D-
lysine and laminin coated plates using the Stem Pro EZ passage tool approximately 14 days 
after beginning neural induction. Neural progenitors were replated at a high density around 3 
weeks of differentiation, switched to neural differentiation medium (NDM) around 4 weeks of 
differentiation, then plated for terminal differentiation around 5 weeks. NDM consisted of 
neurobasal medium, 1% B27, 2 mM L-glutamine, 0.5% pen-strep, non-essential amino acids, 1 
μM ascorbic acid, 200 μM cyclic AMP, 10 ng/mL brain-derived neurotrophic factor, and 10 
ng/mL glial-derived neurotrophic factor. Neurons were maintained in culture until 10 to 17 weeks 
of differentiation. 
CRISPR/Cas9-mediated genome editing 
sgRNAs targeting the isoform translational start sites were designed using MIT’s CRISPR 
design tool (http://crispr.mit.edu) and cloned into the pX459v2.0 vector (Addgene 62988), as 
previously described.95,96 sgRNAs used to generate the UBE3A KO hESC line used here as a 
control have been described previously (Chapter 2). Prior to electroporation or nucleofection, 
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hESCs were treated with ROCK inhibitor (Y-27632; Selleck Chemicals) for 24 hours. hESCs 
were then singlized using Accutase (Millipore) and electroporated using the Gene Pulser X Cell 
(BioRad) or nucleofected using the Amaxa 4D Nucleofector (Lonza). For generation of the 
Isoform1 KO line, hESCs were electroporated in PBS with 10 μg of CRISPR plasmid and 8 μl of 
single-stranded oligonucleotide (ssODN) template. For generation of the Isoform2 KO and 
Isoform3 KO lines, hESCs were nucleofected with 2.5 μg of each CRISPR using the P3 Primary 
Cell Kit L (Lonza). hESCs were then plated onto puromycin-resistant (DR4) irrMEFs at low 
density, supplemented with ROCK inhibitor and L755507 (5 μM, Xcessbio), which has been 
shown to improve efficiency of homology directed repair. 24 hours after plating, cells underwent 
selection for 48 hours with puromycin (0.5 – 1 μg/ ml). Puromycin resistant colonies were 
screened by conventional PCR followed by restriction digest 11-14 days after plating. Putative 
clones were plated onto regular irrMEFs and successful genome editing was confirmed by 
Sanger sequencing. 
Subcellular Fractionation 
Subcellular fractionation was performed using the Cell Fractionation Kit – Standard (abcam) 
according to the manufacturer’s instructions with the following modifications: 1) Protease 
Inhibitor Cocktail III was added to 1x Buffer A at the beginning of the fractionation protocol at a 
1:1000 dilution; 2) a whole cell lysate was collected following the first lysis step by collecting 1/6 
of the volume of lysate - downstream volumes used in the protocol were adjusted accordingly; 
and 3) whole cell and nuclear fractions were sonicated at the end of the protocol to sheer DNA 
using the following settings: [3 seconds on, 3 seconds off] x 2 at 30% amplitude. All fractions 
were stored at -80°C until use. 
Western Blot 
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Equal volumes of lysate from each fraction were separated by SDS-PAGE using 4-20% TGX 
Stain-Free mini gels (BioRad). Protein was transferred to PVDF membrane using the TransBlot 
Turbo system (BioRad). Membranes were blocked in TBS Odyssey Blocking Buffer (LI-COR, 
Inc.) for 1 hour at room temperature then incubated in blocking buffer containing primary 
antibodies overnight at 4°C. Membranes were washed with TBS-T (Tris-buffered saline plus 
0.1% Tween-20) at room temperature, incubated in blocking buffer containing IRDye Secondary 
Antibodies (LI-COR, Inc.) for 1 hour at room temperature, then washed again in TBS-T. All 
washes were done three times for 10-12 minutes each at room temperature. Membranes were 
imaged using the Odyssey imaging machine and software (LI-COR, Inc.). Images were 
quantified using Image Studio Lite (LI-COR, Inc.). The following primary antibodies were used: 
rabbit anti-UBE3A (1:3000; Bethyl A300-351), rabbit anti-UBE3A (1:3000; Bethyl A300-352), 
mouse anti-UBE3A (1:1000; Sigma E8655), rabbit anti-LMNB1 (1:5000; Abcam), mouse anti-
GAPDH (1:10000; Millipore); rabbit anti-BAK (1:1000; Cell Signaling Technologies). The 
following secondary antibodies were used at a concentration of 1:10000: IRDye 800 CW 
Donkey anti-Rabbit, IRDye 680RD Goat anti-Rabbit, and IRDye 680RD Goat anti-Mouse (LI-
COR, Inc.). A Western blot containing only nuclear fractions from all 4 hESC and neuron lines 
was performed with the following changes from above: blocking and antibody incubations were 
done in 5% BSA, anti-rabbit HRP-conjugated secondary antibody (1:3000; Cell Signaling 
Technologies) was used, and the blot was imaged using Clarity Western ECL substrate 
(BioRad) on the ChemiDoc Touch imaging system (BioRad). 
Immunocytochemistry 
hESCs and neurons were grown on glass chamber slides for immunocytochemistry. Cells were 
fixed using room temperature 4% paraformaldehyde for 10 min then permeabilized using 0.5% 
PBS-Triton X 100 (PBS-T) for 10 min at room temperature. Cells were blocked in 0.1% PBS-T 
containing 2% bovine serum albumin and 5% normal goat serum. Cells were incubated in 
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primary antibody in blocking buffer overnight at room temperature then washed with PBS. Cells 
were then incubated in secondary antibody in blocking buffer for 3 hours at room temperature 
then washed with PBS. Cells were mounted with ProLong Gold Anti-Fade Hard Set with DAPI 
(ThermoFisher Scientific) and allowed to set overnight at room temperature before imaging. The 
following primary antibodies were used: mouse anti-UBE3A (1:500; Sigma E8655), rabbit anti-
OCT4 (1:200; Stemgent 09-0023), chicken anti-MAP2 (1:10000; abcam), rabbit anti-NeuN 
(1:300; abcam). The following secondary antibodies were used: anti-mouse Alexa Fluor 488 
(1:400; Invitrogen), anti-rabbit Alexa Fluor 594 (1:400; Invitrogen), anti-chicken Alexa Fluor 647 
(1:250, abcam). Confocal images (134.7 x 134.7um) were acquired with a 63x oil immersion 
lens (numerical aperture 1.4) on a Zeiss 780 confocal system mounted on an inverted Axio 
Observer Z1 (Carl Zeiss, Germany). Pixel dwell time was 1.27 seconds, scan time of 2.34 
seconds and images were averaged 2 times. Three randomly chosen areas of the chamber 
slide were images for each cell line. Z-series were done with a 0.2 μm interval and maximum 
projection images were created using Zeiss ZEN software.  
Electrophysiology 
Neurons were plated onto glass coverslips around 5 weeks of differentiation. Whole-cell voltage 
and current clamp recordings were performed at 12 weeks of differentiation as previously 
described.76  
qRT-PCR 
cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific) according to manufacturer’s instructions. Quantitative RT-PCR was performed 
using Taqman Gene Expression Assays and Mastermix (Thermo Fisher Scientific) on the Step 
One Plus (Thermo Fisher Scientific). Reactions were performed in technical duplicates, with 
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GAPDH Endogenous Control Taqman Assay used as the housekeeping gene for normalization. 
Gene expression was quantified using the ΔΔCt method. 
Immunogold Transmission Electron Microscopy  
Neurons were plated for terminal differentiation onto plastic 4 well plates at 6 weeks of 
differentiation. At 10 weeks, neurons were fixed using 4% paraformaldehyde at room 
temperature for 30 min. Cells were washed in PBS at room temperature, then blocked and 
permeabilized by incubating in 0.1% PBS-T containing 2% bovine serum albumin and 5% 
normal goat serum for 30 min at room temperature. Cells were incubated overnight at room 
temperature in blocking buffer containing primary antibody (mouse anti UBE3A (Sigma) at 
1:250). Cells were washed at room temperature in PBS then incubated in secondary antibody 
for 1 hour at room temperature. Secondary antibody (goat anti-mouse Nanogold Fab) was 
diluted 1:200 in 1% BSA. Cells were washed several times in PBS then washed in deionized 
water. Gold enhancement was performed for 4 min using GoldEnhance (Nanoprobes). Cells 
were rinsed in deionized water to stop enhancement reaction. 
To prepare cells for electron microscopy, cells were rinsed for 5 min in 0.1 M Cacodylate buffer, 
then post-fixed in 1% OsO4, 0.8% Potassium Ferricyanide in 0.1 M Cacodylate buffer for 30 min 
at room temperature. Cells were then washed 5 times in deionized water for 5 min per wash, 
block stained in 1% Uranyl Acetate in deionized water for 30 min at room temperature, then 
washed again 3 times (5 min each) in deionized water. Next cells were dehydrated in ethanol (5 
min in 50% EtOH, 5 min in 75% EtOH, 5 min in 95% EtOH, then 3 incubations in 100% EtOH for 
5 min each), then infiltrated in 100% resin overnight at room temperature. The following day, 
fresh 100% resin was added and the cells were polymerized at 60°C for 48 hours. Thin sections 
of 70-80 nm were cut on the Ultramicrotome Leica EM UC7 and sections placed on Cu grids. 
Sections were counterstained with 6% Uranyl Acetate in 50% methanol for 4 min. Images were 
acquired with the Hitachi H-7650 Transmission Electron Microscope. Electron microscopy 
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preparation and imaging was performed by the UConn Health Central Electron Microscopy 
Facility.  
ChIPseq 
ChIPseq was performed as previously described 109,110 on hESCs, hESC-derived neural 
progenitors (NPCs; 5 weeks of differentiation), and hESC-derived neurons (10 weeks of 
differentiation). Antibodies used in this experiment were as follows: rabbit anti-UBE3A (Bethyl 
A300-351), rabbit anti-UBE3A (Bethyl A300-352), anti-H3K27ac (ab4729, Abcam). Two 
replicate IPs were performed per antibody using approximately 100 μg of chromatin and 10 μg 
of antibody per IP.  
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Results 
Generation of isogenic hESC lines lacking individual protein isoforms 
To study the abundance and localization of the UBE3A protein isoforms, we first 
generated isogenic hESC lines lacking the individual protein isoforms. Isogenic hESCs and 
neurons would allow us to minimize molecular and phenotypic differences caused by normal 
human genetic variation. All three human protein isoforms are full length versions of UBE3A: 
isoforms 2 and 3 have an additional 23 and 20 amino acids, respectively, at their N terminus. 
Because of this, the RNAs encoding the isoforms are nearly identical aside from the exons that 
encode for these additional amino acids.48 The three UBE3A protein isoforms are, however, 
translated from unique translational start sites.47 We took advantage of these three sites in order 
to generate three isogenic hESC lines, each of which lacked an individual protein isoform. Using 
the CRISPR/Cas9 system, we mutated one of the three translational start sites, changing it from 
a methionine to a leucine, which would prevent the translation of the isoform of interest (Figure 
1). Because the methionine that serves as the isoform 1 translational start site is present in the 
other two protein isoforms, we used multiple protein prediction softwares86,87 to find an amino 
acid substitute (leucine) that was predicted to have a benign effect on the other two isoforms 
(Supplemental Figure 1). 
Isoform 1 is the most abundant UBE3A protein isoform 
 To determine the relative abundance of the human UBE3A protein isoforms in hESCs 
and hESC-derived neurons, we examined total UBE3A protein levels in whole cell lysates 
prepared from the isoform knockout and isogenic control lines. Our data indicate that isoform 1 
is the predominant isoform in both cell types – loss of this isoform produced a significant 
reduction in total UBE3A levels in whole cell lysates prepared from both hESCs (Figure 2A/B) 
and neurons (Figure 3A/B). Loss of isoform 2 or isoform 3, however, did not produce any 
significant changes in total UBE3A levels. These data indicate that isoform 1 is the most 
abundant of the three human protein isoforms in hESCs and hESC-derived neurons. 
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All three UBE3A isoforms are predominantly localized to the cytoplasm 
 Because studies of the mouse protein isoforms indicate differences in isoform 
localization,49 we sought to determine whether the human protein isoforms also localized 
differentially. Using a subcellular fractionation protocol, we examined UBE3A abundance in 
cytoplasmic, mitochondrial, and nuclear fractions in both hESCs and neurons. In both cell types, 
UBE3A appears to localize predominantly to the cytoplasm, both in normal and isoform-null 
lines (Figure 2, Figure 3). Consistent with our whole cell results, loss of isoform 1 produced 
significant loss of UBE3A in the cytoplasmic fraction (Figure 2C, Figure 3C), but not the 
mitochondrial or nuclear fractions (Figure 2D/E, Figure 3 D/E). Loss of isoform 2 or isoform 3 
did not cause a significant change in the abundance of UBE3A protein in any cellular fractions 
when compared to the H9 parent line (Figure 2A-E, Figure 3A-E). 
To confirm these results, we also examined UBE3A localization via 
immunocytochemistry. We first stained hESCs for UBE3A and OCT3/4, a transcription factor 
and pluripotency marker known to localize to the nucleus (Figure 2F, Supplemental Figure 3). 
Here we included a UBE3A KO hESC line to serve as an additional control (Supplemental 
Figure 3). Consistent with our fractionation results, expression of UBE3A in hESCs appears to 
be predominantly cytoplasmic, as there is expression of UBE3A outside of the area positive for 
OCT3/4 staining. We next stained hESC-derived neurons for UBE3A and MAP2, a microtubule 
protein that localizes to the cytoplasm and is a marker for post-mitotic neurons (Figure 3C, 
Supplemental Figure 4A). Although the strongest UBE3A signal appears in the nucleus, there 
is still obvious UBE3A signal in the processes and in the area of the soma outside of the 
nucleus (Supplemental Figure 4A & 5).  
Studies of UBE3A localization in mouse brain indicate that UBE3A is initially expressed 
in the cytoplasm but becomes increasingly nuclear upon postnatal maturation.111 To determine 
whether the intense staining in the soma was nuclear UBE3A, we stained neurons for UBE3A 
and NeuN, which is predominantly expressed in the nucleus and, to a lesser extent, in the 
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processes, of mature neurons. Comparison of the UBE3A signal with both NeuN and DAPI 
shows that the intense UBE3A signal in the soma colocalizes with both of these nuclear 
markers (Supplemental Figure 4B), but only to a certain extent (Supplemental Figure 4B, 
arrows). 
Because the results of the immunostaining show a stronger UBE3A nuclear signal than 
the subcellular fractionations, we sought to further confirm the results from each procedure. We 
first confirmed the results of our fractionation protocol by using a second UBE3A primary 
antibody, which reacts to a different portion of the protein (N terminus versus HECT domain; 
Supplemental Figure 6A). Next, we wanted to see if perhaps our nuclear fractions were simply 
too diluted or run at too small of a volume to see robust nuclear UBE3A bands. To do this, we 
ran a Western blot using a larger volume of lysate that was intentionally exposed to the point of 
saturation (3 min; Supplemental Figure 6B), which showed a faint signal. Finally, we 
performed a Western blot using the same primary antibody that is used for the immunostaining 
(Supplemental Figure 6C). Interestingly, although we do not see a band in the nuclear 
fractions at the expected UBE3A size of 100 kDa, we do see a band that only appears in the 
whole cell and nuclear fraction lysates that is less than 75 kDa in size. It is possible that this 
unknown 75 kDa protein is also causing the increased nuclear signal when we perform 
immunostaining, as this band does not appear when using other UBE3A antibodies (for 
comparison, see Figure 2A, 3A, and Supplemental Figure 6A).  
To confirm the results of our immunostaining, we examined UBE3A localization in 
neurons by transmission electron microscopy. These results showed diffuse UBE3A puncta in 
the soma both within and outside of nucleus (Supplemental Figure 7A-B), as well as in the 
neuronal processes (Supplemental Figure 7C). Finally, we investigated whether the small 
proportion of UBE3A that is localized to the nuclear is capable of acting as a transcriptional co-
activator.40 ChIP-seq for UBE3A using two different primary antibodies showed that UBE3A did 
not preferentially bind to DNA in NPCs or neurons (Supplemental Figure 8A). 
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Isoform 1-null neurons recapitulate some AS phenotypes 
 We last wanted to determine whether neurons lacking the individual UBE3A protein 
isoforms displayed any in vitro AS phenotypes. Based on our results examining the abundance 
of the isoforms (Figure 3A-B), and our knowledge of the AS patients with isoform 1 translational 
start site mutations,77 we hypothesized that loss of isoform 1 would produce AS phenotypes in 
hESC-derived neurons while loss of the other two isoforms would likely would not produce any 
phenotype. Previously we established that AS iPSC-derived neurons exhibit a phenotype of 
impaired electrical maturation, as indicated by a more depolarized resting membrane potential 
(RMP), immature patterns of action potential firing, and decreased frequency of spontaneous 
excitatory synaptic activity.76 We examined these three phenotypes in our isoform-null and 
isogenic control neurons at 12 weeks of differentiation. Isoform 1 KO neurons displayed a more 
depolarized resting membrane potential compared to controls, while there were no differences 
in the isoform 2 KO or isoform 3 KO neurons (Figure 4A). Interestingly, there were no 
differences in action potential firing (Figure 4B) or synaptic activity (Figure 4C) in the any of the 
isoform-null neurons, indicating that the isoform 1 KO neurons only display some AS electrical 
phenotypes. 
 Finally, we wanted to examine whether the isoform-null neurons displayed any molecular 
AS phenotypes. Recently we established and validated a list of genes that are consistently 
differentially expressed in AS stem cell-derived neurons when compared to isogenic controls by 
mRNAseq. We chose to examine the expression of a handful of these AS genes in the isoform 
1 KO neurons, as they most closely resemble AS neurons in terms of their UBE3A protein levels 
and electrical phenotype. We examined the expression of 6 genes: MGP, GJA5, TBX18, TBR1, 
NEUROD2, and EDNRA (Figure 4D). Four of these genes (TBX18, TBR1, NEUROD2, EDNRA) 
were significantly differentially expressed in the Isoform 1 KO neurons in the same manner as 
AS neurons (Student’s t-test, p < 0.05), while GJA5 was not different between the two lines. 
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Unexpectedly, MGP was actually decreased in the Isoform 1 KO neurons. Together these data 
indicate that the Isoform 1 KO neurons recapitulate some, but not all, AS phenotypes in vitro. 
Discussion 
 The human UBE3A gene encodes for an E3 ubiquitin ligase that has three known 
protein isoforms.46 Surprisingly little is known about the human isoforms, however studies in 
mouse indicate that the isoforms may have differences in localization and function.49,50 Here we 
have used the CRISPR/Cas9 system to generate hESCs lacking these individual isoforms and 
studied their abundance and localization in both hESCs and neurons. We have also examined 
the phenotype of neurons lacking the individual isoforms. We have shown that human isoform 1 
is the most abundant of the three isoforms, accounting for almost ninety percent of total UBE3A 
protein in these two cell types. We have also shown that in both hESCs and neurons, UBE3A 
localizes predominantly to the cytoplasm, independent of which isoform is absent or present, 
with low levels of expression in the nucleus. Finally, we have shown that neurons lacking 
isoform 1 display some in vitro AS phenotypes, in terms of their electrical properties and gene 
expression. 
 To examine the localization of the UBE3A isoforms, we used two approaches: 
subcellular fractionation and immunocytochemistry. Both approaches showed that isoform 1 is 
the predominant protein isoform and that all isoforms are most abundant in the cytoplasm. Loss 
of individual isoforms did not change the localization of UBE3A using either approach. 
Interestingly, we appeared to see more UBE3A in the nucleus of normal and isoform-null 
neurons via immunostaining, as shown by colocalization with DAPI and NeuN, than would be 
anticipated based on the results of our fractionations. However, the amount of UBE3A that we 
see in normal neurons by TEM appears to agree with the fractionation results.  
We believe that the strong UBE3A nuclear UBE3A signal that we see by immunostaining 
is likely due to the fact that the small amount of UBE3A that is localized to the nucleus is 
contained within a much smaller volume than the cytosolic UBE3A, which is spread out across 
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the volume of the entire neuron and its processes. It is also possible, based on our Western blot 
using the same primary antibody, that the strong nuclear UBE3A signal is related to the >75 
kDa band that we see via Western blot. Based on our knowledge of UBE3A localization in the 
developing mouse brain,111 it is also possible that human UBE3A becomes increasingly nuclear 
during the course of human brain development, but that our neurons are developmentally too 
immature to display these changes in localization. 
Interestingly, although isoform 1-null neurons lack the majority of the total UBE3A 
protein, they do not fully recapitulate AS electrical and molecular phenotypes. Isoform 1-null 
neurons have a more depolarized resting membrane potential compared to the other three 
neuron lines, however, the RMP of these neurons would still be considered mature for their 
stage of in vitro differentiation. We hypothesize that the difference in RMP between isoform 1-
null neurons and their isogenic controls would be even more pronounced at an earlier age, such 
as 9 to 10 weeks in vitro. Additionally, this more mature RMP seen in all four neuron lines is 
also consistent with their action potential firing pattern, as most neurons were capable of firing 
single or mature trains of action potentials. Another possibility is that, even though loss of 
isoform 1 dramatically reduces total UBE3A levels in our stem cells and neurons, in vitro AS 
phenotypes are truly the result of loss of two or more of the protein isoforms. Future studies 
should examine the effects of the combined loss of two isoforms at a time to further elucidate 
their role in the electrical maturity of normal and AS neurons, as well as examine these 
phenotypes at various stages of neuronal development in our isoform-null neurons. 
We have also shown here that isoform 1 accounts for the majority of UBE3A protein in 
hESCs and neurons, while isoforms 2 and 3 appear to account for very little protein at this 
stage. This knowledge of the isoforms’ abundance is important for the development of AS 
therapies. One promising therapeutic avenue currently being explored for AS is the introduction 
of a UBE3A transgene through vector-based therapies,71 which typically can only contain one 
cDNA at a time. Replacement of all three human isoforms using this approach, therefore, would 
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likely require the development of three separate vectors. Based on the results shown here, it is 
possible that delivery of isoform 1 alone may be a useful therapeutic approach, as it accounts 
for the majority of total UBE3A protein in human neurons in vitro. Future studies should examine 
whether introduction of individual UBE3A protein isoforms into human AS neurons in vitro is 
capable of restoring their phenotypes. 
 In summary, we have used isogenic isoform-null hESCS and hESC-derived neurons to 
examine the relative abundance and localization of the human UBE3A protein isoforms. We 
have shown that isoform 1 is the most abundant, and that most UBE3A protein localizes to the 
cytoplasm in both cell types, independent of the specific isoform. We have also demonstrated 
that neurons lacking isoform 1 recapitulate some, but not all, in vitro AS phenotypes. This 
knowledge is not only important for the study of AS, but also the development of potential AS 
therapies. 
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Figure 1. Generation of isogenic isoform-null hESC lines 
A Schematic illustrating isoform translational start sites and proposed genome editing. Arrows 
indicate primers used for screening. Scissors indicate CRISPR cut sites. Blue box = exon; grey 
line = intron; green = methionine used as start site B-D Sanger sequencing showing mutation of 
translational start site (ATG) for isoform 1 (B), isoform 2 (C), and isoform 3 (D). Arrows indicate 
locations of changed nucleotides. 
101 
 
 
 
Figure 2. Abundance and localization of UBE3A isoforms in hESCs 
A Western blot showing UBE3A levels in subcellular fractions from H9 and isoform-null hESC 
lines. W = whole cell lysate, C = cytoplasmic fraction, M = mitochondrial fraction, N = nuclear 
fraction. B-E Quantification of Western blots for each fraction. Graphs show average percentage 
of appropriate loading control (n = 4 fractionations). Error bars: standard error of the mean.  
* p < 0.05 *** p < 0.005 (univariate ANOVA) F Immunocytochemistry for UBE3A in H9 hESCS 
shows that UBE3A is cytoplasmic, in agreement with above fractionation results. Scale bar 20 
μm 
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Figure 3. Abundance and localization of UBE3A isoforms in neurons 
A Western blot showing UBE3A levels in subcellular fractions from H9 and isoform-null neurons. 
W = whole cell lysate, C = cytoplasmic fraction, M = mitochondrial fraction, N = nuclear fraction. 
B-E Quantification of Western blots for each fraction. Graphs show average percentage of 
appropriate loading control (n = 3 fractionations). Error bars: standard error of the mean.  
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* p < 0.05 *** p < 0.005 (univariate ANOVA) F Immunocytochemistry for UBE3A in H9 neurons 
shows that UBE3A is highly concentrated in the nucleus (top), but also is expressed in the 
cytoplasm (bottom). Box in top row indicates region in bottom row. Scale bar 20 μm (top), 10 μm 
(bottom). 
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Figure 4. Isoform 1-null neurons partially recapitulate AS cellular phenotypes 
A Isoform-1 null neurons have a more depolarized resting membrane potential. * p < 0.05 
(univariate ANOVA) B No significant differences in … (continued on next page) 
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action potential (AP) firing upon loss of any UBE3A isoforms Left: AP characterization in 
isoform-null neurons; right: sample AP traces C Isoform-null neurons do not have any significant 
differences in spontaneous excitatory synaptic activity. n = 39-40 cells on 3 coverslips per cell 
line. D Loss of isoform 1 affects expression of some, but not all, genes differentially expressed 
in AS neurons, as assayed by qRT-PCR * p < 0.05, *** p < 0.005, **** p < 0.001 (student’s t-
test) 
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Figure S1.  Effect of proposed amino acid change on isoform 2 (A) and isoform 3 (B) 
protein. Top: results from Predict Protein software showing effects of every possible amino acid 
substitution of the methionine. Bottom: results from Predict SNP software showing predicted 
effects of L to M substitution from 7 different structure prediction algorithms. 
 
  
A 
B 
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Figure S2. Characterization of isoform-null hESCs  
A qRT-PCR results showing UBE3A expression in H9 and isoform-null hESCs B qRT-PCR 
results showing expression of pluripotency genes in H9 and isoform-null hESCs 
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Figure S3. UBE3A expression in isoform-null hESCs by immunocytochemistry 
Abundant expression of UBE3A is seen in the cytoplasm in all isoform-null cell lines, indicating 
that the localization of UBE3A does not differ upon loss of any isoform. Isoform 1-null hESCs 
show dramatically reduced protein levels. UBE3A KO hESCs were included as a negative 
control. OCT3/4 staining was included to show localization of a known nuclear protein. Scale 
bar 20 μm 
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Figure S4. UBE3A expression in neurons by immunocytochemistry 
A UBE3A signal appears to localize predominantly to the nucleus by immunostaining in 
neurons, in contradiction to fractionation results. B Comparing localization of UBE3A with 
localization of NeuN, a nuclear marker, shows strong UBE3A signal outside of the nucleus 
(arrows). Scale bar 20 μm 
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Figure S5. Maximum projection images from Z stack shows cytoplasmic UBE3A 
expression in all four neuron lines Scale bar 20 μm 
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Figure S6. Additional UBE3A Western blots 
A Confirmation of fractionation results in H9 hESCs and neurons using a secondary UBE3A 
primary antibody B Overexposure of nuclear fractions from hESCs and neurons show faint 
nuclear UBE3A signal C Western blot using same primary antibody used for ICC on lysates 
from H9 neurons confirms findings from fractionations. Presence of smaller nuclear band could 
explain intense nuclear signal in ICC images. * expected UBE3A size, < shorter band seen only 
in whole cell and nuclear fractions 
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Figure S7. Transmission electron microscopy images show diffuse UBE3A localization in 
cytoplasm and nucleus in H9 neurons 
A Immunogold labeling shows diffuse UBE3A staining (white triangles) in the nucleus and soma 
(middle image) as well as in the neuronal processes (right image). Examples of non-specific 
puncta are indicated by black arrows. Scale bar 2 μm B No primary control image. Scale bar 
500 nm 
  
A 
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Figure S8. ChIPseq indicates that nuclear UBE3A does not directly bind to DNA in NPCs 
or neurons 
A ChIPseq peaks in 15q11-q13 region. Top (red): H3K27ac ChIPseq performed in UBE3A KO 
hESCs as a positive control. Bottom (pink): UBE3A ChIPseq indicates no specific binding 
anywhere in the genome (15q11-q13.1 region shown here as an example) in either H9 NPCs or 
H9 neurons. UBE3A KO hESCs were included as a negative control. B IP showing that the 
antibodies used for ChIPseq are capable of … (continued on next page) 
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pulling down UBE3A protein. Left image: IP was performed with antibody 1 then the membrane 
was blotted with antibody 2. Right image: IP was performed with antibody 2 then the membrane 
was blotted with antibody 1. 
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Table 1. sgRNAs used to generate stem cell lines 
Cell Line sgRNA sequence + PAM 
Isoform 1 start site mut. CCGAATGTAAGTGTAACTTGGTT 
Isoform 2 start site mut. AAAAGGAGTGGCTTGCAGGATGG 
Isoform 3 start site mut. ATCACCCTGATGTCACCGAATGG 
 
Table 2. ssODNs used to generate stem cell lines 
Cell Line/Project ssODN sequence 
Isoform 1 start site 
mutation (H9) 
AGAACCTCAGTCTGACGACATTGAAGCTAGTCGATTGTAA 
GTGTAACTTGGTTGAGACTGTGGTTCTTAT 
Isoform 2 start site 
mutation (H9) 
ATTCAAATGGTGGCTCACTTCCAATAACACTGGTGAAGCTTCTCGA 
GCCTGCAAGCCACTCCTTTTACCTCCACTGTAACTCTCTAGGAGAG 
Isoform 3 start site 
mutation (H9) 
TGTAAAATAATTCAAAATTACCTTTTACAAGCTGTTGCAAGTCGGTG 
ACATCAGGGTGATCACAGCTTTGAGTCACTGATTAAAAA 
 
Table 3. Primer Sequences Used for Genome Editing 
Primer Name Letter/Number in Fig. Sequence 
Iso1R L  CTGCTACCAGGGAAGCAAAA 
Iso1SeqF M TTCTTTCATGTTGACATCTTTAATTTT 
Iso1F N  GCTTATAATGGCTTGTCTGTTGG 
Iso2R O TGAAACAATAACCAAATAACATTGG 
Iso2SeqR P TCTTGATTTGAATCGCAGAAAA 
Iso2F Q TCAGTAGCCACTATCAAAGACCT 
Iso3R R TTTTTGAACAATGAATTGGGTTT 
Iso3SeqF S AGCCTACGCTCAGATCAAGG 
Iso3F T TTTTTGAACAATGAATTGGGTTT 
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Chapter 5 
Discussion 
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Summary & Significance 
 AS is a rare neurodevelopmental disorder for which there is currently no cure, and for 
which there is no effective treatment.20 There are, however, multiple promising therapeutic 
approaches currently being explored. These approaches are based on the use of the human 
UBE3A sequence: one approach involves unsilencing the paternal copy of UBE3A by targeting 
the UBE3A-ATS transcript70 while another involves delivery and expression of human UBE3A 
cDNA via vector-based approaches, such as AAV.71 Testing these therapies in a mouse model 
requires the use of the murine sequence or development of a humanized mouse model, which 
is often expensive. It is therefore necessary for the AS field to develop models using human 
cells which can be used to test these potential therapies. Of additional importance is 
establishing robust cellular phenotypes that can be assayed following delivery of these and 
other potential therapies. Human pluripotent stem cells provide us with a tool to achieve both of 
these major milestones. One way to improve in vitro disease models is through the generation 
of isogenic pluripotent stem cell lines, which can be differentiated into neurons. Using isogenic 
cell lines eliminates the natural variation between unrelated individuals, which can in turn cause 
molecular and phenotypic variation even when comparing neurons derived from individuals 
considered to be neurotypical.73,74 Work in this thesis details the generation of isogenic AS and 
control human pluripotent stem cell (hPSC) lines and establishes the use of these cells and their 
neuronal derivatives as robust cellular models to study AS.  
 In chapter 2, I outline the generation of several isogenic iPSC and hESC lines. Some of 
these lines were used in chapters 3 and 4 of this thesis. Some of these lines have also been 
used by others to establish other in vitro AS phenotypes, such as differences in 
electrophysiological properties76 or in neuronal morphology. While these phenotypes can be 
(and have been) established in non-isogenic neurons, they require significantly more patient-
derived lines and more neurons measure from each line to counter natural variation between 
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the cells. Isogenic AS and control pairs will allow us to measure these same phenotypes using 
fewer cell lines and/or total numbers of cells overall. Additionally, these isogenic cell lines allow 
us to ask specific genetic questions of these phenotypes, such as which in vitro phenotypes are 
consistently recapitulated in AS neurons due to loss of UBE3A, and not due to the decreased 
expression of non-imprinted genes that occurs in a large proportion of AS cases (due to large 
deletions of 15q11-q13). 
 Two of the isogenic stem cell lines generated in chapter 2 were used in chapter 3 to 
establish a quantitative molecular AS phenotype by comparing the transcriptomes of AS and 
control neurons. Using conservative criteria, I found 855 genes that were commonly 
differentially expressed in each AS line when compared to their respective isogenic control. 
Importantly, this phenotype was established in cell lines that lacked either UBE3A expression or 
function, allowing us to establish a list of genes that we should be able to reliably assay in cells 
derived from any AS patient subtype in the future (large 15q11-q13 deletion, UPD, etc.). I then 
validated the use of these genes as a phenotype by rescuing some of these gene expression 
changes after restoring ubiquitin ligase function to a ligase-dead version of UBE3A, which was 
achieved by the introduction of the E6 oncoprotein to AS NPCs. Based on our findings, I 
propose that this molecular phenotype, which can be assayed in a manner that is relatively high 
throughput, can and should be used to assess the efficacy of potential therapies being tested in 
cultured human AS neurons, particularly those that are meant to restore the expression or 
function of UBE3A. 
 In chapter 4, I utilized isogenic stem cell lines that had a mutation at one of the three 
UBE3A protein isoform translational start sites, creating hESCs that lacked either protein 
isoform 1, 2, or 3. At the time of writing, there have been few published studies examining the 
human protein isoforms. Increased understanding of these human protein isoforms is important 
given that the mouse and human isoforms are not completely conserved. For vector-based 
gene therapy approaches, knowledge of the isoforms is especially important as each isoform 
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would potentially need to be delivered in separate vectors if all three need to be replaced in AS 
patients. Using our isogenic lines, I demonstrated that isoform 1 accounts for the majority of 
total UBE3A protein in both hESCs and hESC-derived neurons. I also showed that UBE3A 
predominantly localizes to the cytoplasm in these cell types, that loss of isoform 1 dramatically 
reduces cytoplasmic protein levels, and that loss of isoforms 2 and 3 does not appear to affect 
the abundance of UBE3A in any of the subcellular locations examined (cytoplasm, 
mitochondria, nucleus). Furthermore, I showed that isoform 1-null neurons recapitulate some, 
but not all, AS phenotypes. 
Future Directions  
Additional uses for the isogenic stem cell lines 
 The isogenic lines used to establish the molecular AS phenotype would be useful tools 
for addressing several other AS questions. One major question in the AS field is: what are 
UBE3A’s targets in neurons? Based on the existence of AS-causing mutations in the UBE3A 
gene that result in a truncated protein or a ligase-dead protein, it can be assumed that loss of 
UBE3A’s E3 ligase function is a major cause of the phenotypes seen in AS. Efforts to identify 
and validate UBE3A’s targets in neurons have unfortunately not been successful. One potential 
use for our isogenic cell lines, especially the point mutation and its corrected control, would be 
to perform proteomic analyses to establish a list of proteins that are increased in the AS 
compared to the control neurons. Because the point mutation specifically causes loss of 
UBE3A’s ligase function, the proteins identified in this analysis would include accumulated 
substrates that can no longer be targeted for proteasomal degradation and potentially 
downstream changes in secondary proteins. Then, to better discern the direct targets of UBE3A, 
one could acutely knockdown UBE3A in the isogenic control neurons, or any normal neuron, 
and see which of the targets identified in the first experiment are still affected. Another use for 
the isogenic lines would be to perform mixing experiments to determine whether in vitro AS 
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phenotypes are cell intrinsic or whether they are a result of a more global neuronal disfunction. 
For example, one could add a small portion of AS neurons to isogenic controls (such as the AS 
point mutant and its isogenic control) and determine whether the AS neurons still exhibit 
impaired synaptic function or morphological phenotypes. 
Transcriptome Phenotype 
 Our main goal in establishing a molecular transcriptome phenotype for AS was to have a 
phenotype that reflected the loss of UBE3A in AS neurons that could be assayed following 
restoration of UBE3A’s expression or function. The most promising therapeutic approach for AS 
is to use antisense oligonucleotides designed to target the UBE3A-ATS transcript, which, upon 
its degradation, would reactivate the paternal copy of UBE3A.70 This therapy would be specific 
to the human genetic sequence, and would therefore need to be tested in either a humanized 
mouse model, a time consuming and expensive endeavor, or in human neurons. With this 
transcriptome phenotype, we can now treat any of our AS iPSC-derived neurons with these 
ASOs and measure the extent to which the transcriptome phenotype is restored upon activation 
of paternal UBE3A and also determine the effects of the timing of UBE3A restoration. While 
performing mRNAseq would give the most thorough assessment of the degree of phenotype 
restoration, it is also possible to use a less expensive and less time-consuming approach to 
assay phenotype restoration in a subset of the DE genes, such as targeted RNAseq or custom 
qRT-PCR arrays.  
 In addition to establishing our molecular AS phenotype, it is possible to gain further 
insight into our AS neurons from our mRNAseq data. Although I used conservative criteria to 
establish our gene list, gene ontology (GO) analysis of these genes revealed dysregulation of 
pathways or processes that could be further explored. One striking finding was that the top GO 
cluster for the downregulated DE genes involved the terms “synaptic signaling”, “trans-synaptic 
signaling”, and “chemical synaptic transmission”. Interestingly, we also see synaptic phenotypes 
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in our AS stem cell-derived neurons.76 It’s possible that the subset of synaptic genes highlighted 
by GO will give us insight into these synaptic deficits. The top GO clusters for upregulated DE 
genes included terms involved in cell adhesion and the extracellular matrix. These processes 
could be examined in our cultured AS neurons to see whether they are affected and whether 
they can be quantified as it could reflect another in vitro AS neuron phenotype. 
 One caveat to our transcriptome phenotype is that it is only a phenotype for forebrain 
glutamatergic neurons, the major constituent of our cell cultures. However, studies in AS mouse 
models have indicated that GABAergic neurons likely also have deficits in AS.112 Therefore, it 
would be worth establishing a transcriptome phenotype for AS in isogenic GABAergic stem cell-
derived neurons. This would provide insight into genes that are commonly differentially 
expressed in both neuron subtypes, but also tell us which differentially expressed genes are 
unique to each neuronal subtype. 
E6 and UBE3A activation 
 In addition to validating our transcriptome phenotype, our experiments involving E6 
oncoprotein provide an exciting proof of principle that allosteric activation of UBE3A via E6 
could potentially restore ligase function to UBE3A in a subset of AS patients. Treatment of our 
AS NPCs with E6 was able to restore the resting membrane potential phenotype, as well as 
rescue expression of certain genes. Data from in vitro ubiquitination assays, shown here and in 
other studies, indicate that E6 acts as an allosteric activator of wildtype UBE3A and can further 
increase its ligase activity.41 While I am not suggesting that E6 expression itself could serve as a 
potential AS therapy, it might be possible to identify small molecules or peptides that can 
similarly serve as allosteric UBE3A activators. It is possible that, in cases where an AS-causing 
mutation does not cause a complete loss of UBE3A protein, allosteric activation of the 
remaining UBE3A protein could restore ligase activity to therapeutically useful levels. In the 
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future, we plan to test this hypothesis by delivering E6 to AS NPCs known to have low levels of 
UBE3A expression remaining, such as the isoform 1 KO line discussed in chapter 4. 
Studying the UBE3A protein isoforms 
 Although I gained insight into the abundance and localization of the human protein 
isoforms using our isogenic isoform-null stem cell lines, there are further studies that should be 
performed to confirm our results. First, it would be useful to generate double isoform knockout 
lines to confirm our findings that 1) isoform 1 is the predominant isoform, 2) loss of isoforms 2 or 
3 do not seem to affect total UBE3A abundance (consistent with isoform 1 being the 
predominant isoform), and 3) UBE3A predominantly localizes to the cytoplasm, regardless of 
protein isoform. If our conclusions are correct, I would expect that double isoform-null lines 
would recapitulate these results by showing relatively normal protein levels in isoform 2/3-null 
cells and localization of remaining UBE3A to the cytoplasm, by both fractionation and 
immunostaining, in all isoform double-null combinations. Another question is whether the 
isoforms have different targets, as all three isoforms are full length and presumably are 
functional E3 ligases. It might be possible to overexpress individual UBE3A isoforms in UBE3A 
null cells and examine proteomic changes in the cells. 
 One major motivation for studying the human protein isoforms is that the knowledge 
gained could be useful in the development of vector-based gene therapies. This approach 
involves treating AS patients with a vector containing a UBE3A transgene, which would then 
allow the patient to express normal UBE3A protein. The vectors being investigated for this 
approach would likely only be able to express individual cDNAs, which would mean that a vector 
expressing each isoform would need to be made. This potentially means that three different 
vectors would have to be used. However, it is also possible that not all three isoforms would 
need to be delivered to a patient to have a therapeutic effect. One future study would be to treat 
AS NPCs or neurons with virus expressing only one of the three isoforms to see whether we 
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could rescue any of our in vitro AS phenotypes, or whether a combination of two or more 
isoforms is necessary to restore these phenotypes. 
Conclusions 
 In this thesis, I have developed several isogenic iPSC and hESC lines that can be used 
as robust cellular AS models. I have used these isogenic lines to establish a quantitative 
molecular phenotype for AS neurons that can be assayed following drug treatments. Still other 
isogenic lines established in this thesis have been used to study the human UBE3A protein 
isoforms, about which little information is currently known. Finally, I have validated these cell 
lines and have made them available so that others may also use them to make important AS 
discoveries. Ultimately, I hope that these lines can be used toward the development of effective 
therapies for AS. 
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